Blog

Home/Blog
Blog2019-08-20T10:39:44-05:00

Categories

Recent Posts

Archives

FDA Approves Ensacove (ensartinib) for Locally Advanced or Metastatic ALK-Positive NSCLC

December 19th, 2024|Hot Topics, News, Science and Research|

On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy.  Ensacove (ensartinib) represents a new first-line treatment option for those [...]

The Women and Lung Cancer Research and Preventive Services Act Passes!

December 17th, 2024|Advocacy in Action, Hot Topics, News|

Yesterday, the Women and Lung Cancer Research and Preventive Services Act  (H.R. 4534/S. 2245) achieved a historic milestone and passed out of the House of Representatives. We thank the bill leaders, Congressman Brendan F. Boyle (D-PA-02) and Congressman Brian Fitzpatrick (R-PA-01), for their joint effort and statement. We also [...]

Living Room Show Notes: Shared Decision-Making & Second Opinions

December 16th, 2024|Hot Topics, Newsletter Articles, Your Community|

Shared decision-making and seeking second opinions are important parts of the healthcare process that can improve patient care.   Dr. David Gandara from UC Davis Comprehensive Cancer Center joined GO2’s November 2024 Lung Cancer Living Room® to discuss how he works with patients to consider evidence, the provider's knowledge, and [...]

FDA Approves Bizengri (zenocutuzumab-zbco) for Metastatic NRG1-Positive NSCLC

December 6th, 2024|Hot Topics, News, Science and Research|

On Dec. 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Bizengri (zenocutuzumab-zbco) for people with metastatic non-small cell lung cancer (NSCLC) who have an NRG1 mutation following progression on or after prior systemic therapy. Bizengri (zenocutuzumab-zbco) was also approved for the same group of [...]

FDA Approves Imfinzi (durvalumab) as First-Line Therapy for Limited-Stage SCLC

December 6th, 2024|Hot Topics, News, Science and Research|

On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the use of Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease did not progress following combination platinum-based chemotherapy and radiation. Previously approved in combination with chemotherapy for untreated extensive-stage small cell lung [...]

An Oncologist’s View: Navigating the Unique Challenges of Transformed Small Cell Lung Cancer

December 2nd, 2024|Hot Topics, Magnifying LeNS, News, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill  It is common for cancer cells to change over time as people [...]

A Year in Review: GO2’s Research Impact on the Lung Cancer Community 

December 2nd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation; Andrew Ciupek, PhD, Associate Director, Clinical Research; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research; Heather Law, MA, Associate Director, Lung Cancer Registry; Richard Erwin, Executive Director of the Addario Lung Cancer Medical Institute; Courtney Granville, PhD, MSPH, Chief [...]

How to Find Trustworthy Lung Cancer Information Online

December 2nd, 2024|Hot Topics, Magnifying LeNS, News, Newsletter Articles, Science and Research|

By Renee Botello MSc, Treatment and Trials Navigator   A lung cancer diagnosis can be overwhelming and is life-changing for patients and caregivers. Navigating it is challenging without the correct information. The internet has become many people's primary source for understanding a diagnosis and other health-related issues. But [...]

How One Survivor Became an Advocate: Perspectives from a Voices Summit 1st-Timer

November 21st, 2024|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles|

In March 2024, Oakland-based photographer Genevieve S. joined lung cancer advocates in Washington, D.C., to share her story and urge support for lung cancer research with members of Congress. We spoke with her about her experience as 1 of 109 first-time GO2 for Lung Cancer Voices Summit participants. How [...]

GO2 for Lung Cancer Honors and Celebrates Its Community at 19th Annual Simply the Best Gala

November 6th, 2024|Hot Topics, News, Press Releases|

GO2 for Lung Cancer (GO2) recognized lung cancer champions at its 19th Annual Simply the Best Gala in San Francisco on Nov. 2. This event celebrated organizations and individuals across the lung cancer community, including industry partners, survivors, caregivers, and donors.  “Each year, we look forward to recognizing the [...]

Treating EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)

November 4th, 2024|Hot Topics, Newsletter Articles, Your Community|

Treatment strategies for non-small cell lung cancer (NSCLC) with EGFR mutations have evolved in recent years, including the development and approval of new therapies and combinations of treatments. The best treatment for each person with EGFR NSCLC depends on many factors, including the specific EGFR mutation, whether brain metastases [...]

GO2 for Lung Cancer to Present Awards to Partners Who Have Gone Above and Beyond to Confront Lung Cancer

October 24th, 2024|Hot Topics, News, Press Releases|

WASHINGTON, Oct. 23, 2024—GO2 for Lung Cancer (GO2) will honor Novocure at its 19th annual “Simply the Best” Gala on Saturday, Nov. 2 at the Fairmont Hotel in San Francisco.  Novocure will receive the 2024 “GO2 Excellence Award in Advancing Innovative Precision Medicine” for its leadership in developing novel [...]

Perspectives from the 2024 World Conference on Lung Cancer

October 24th, 2024|Community Engagement, Hot Topics, Science and Research|

Recently, lung cancer professionals from across the globe gathered to connect and discuss developments impacting the lung cancer community at the International Association for the Study of Lung Cancer (IASLC)’s World Conference for Lung Cancer (WCLC) in San Diego, CA. This year, IASLC celebrated its 50th anniversary at WCLC. [...]

Faith & resilience: May O.’s Inspiring Journey

October 21st, 2024|Hot Topics, Newsletter Articles, Spotlights, Stories of Hope, Survivors, Women, Your Community|

May O. is a 40-year-old warrior, wife, and mother thriving with metastatic lung cancer in Houston, TX. She has a positive outlook on her situation and views it as a blessing. She loves spending time with her husband, Darren, and her 3-year-old daughter, Mia. She loves gardening, cooking, baking, [...]

FDA Approves the Wearable Optune Lua Device for Metastatic NSCLC

October 16th, 2024|Hot Topics, News, Science and Research|

On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.   Optune [...]

FDA Approves the Wearable Optune Lua Device for Metastatic NSCLC

October 16th, 2024|Hot Topics, News, Science and Research|

On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.   Optune Lua [...]

Living Room Show Notes: What’s New in Radiation Therapy

October 8th, 2024|Hot Topics, News, Newsletter Articles, Your Community|

Radiation therapy for lung cancer has seen recent advancements that have improved accuracy and treatment outcomes. Dr. Dan Schiffner from Sutter Health Palo Alto Medical Foundation joined GO2’s September 2024 Lung Cancer Living Room to discuss a radiation oncologist’s role in treating lung cancer. He explained the different types of [...]

FDA Approves Opdivo (nivolumab) for Resectable NSCLC

October 4th, 2024|Hot Topics, News, Science and Research|

On October 3, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) to be used with platinum-doublet chemotherapy as a treatment before surgery, followed by Opdivo (nivolumab) alone after surgery. This approval is for people with resectable (removable by surgery) non-small cell lung cancer (NSCLC) who do not [...]

FDA Approves Tagrisso (osimertinib) for Stage 3 (III) NSCLC Following Chemoradiation 

September 27th, 2024|Hot Topics, News, Science and Research|

On September 25, 2024, the U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for people with unresectable stage 3 (III) non-small cell lung cancer (NSCLC). It’s approved for people who have both:  Disease that has not progressed during or after chemoradiation therapy, and Tumors that have EGFR exon [...]

FDA Approves New Combination Therapy for People with Advanced EGFR+ NSCLC

September 20th, 2024|Hot Topics, News, Science and Research|

On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this new combination therapy for people with non-small cell lung cancer [...]

“My Caregiver, My Rock”

September 19th, 2024|Hot Topics, Stories of Hope|

In 2023, Sven received the GO2 Caregiver Award at GO2’s annual gala. This award recognizes people who go above and beyond the call of duty to care for a loved one facing lung cancer. Sven cared for his late wife Elizabeth (Libby), who was diagnosed in 2016 at age [...]

FDA Approves New Administration Method for Tecentriq (atezolizumab)

September 16th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that the FDA previously approved for adults, including treatments for both [...]

Joelle Fathi: Unlocking the Origins of Lung Cancer

September 16th, 2024|Hot Topics, Monthly Measure, News, Small Cell Lung Cancer Spotlight, Stories of Hope, Women|

GO2 for Lung Cancer Chief Healthcare Delivery Officer Joelle Fathi, DNP, RN, ARNP, CTTS, FAANP, FAAN has a family history of lung cancer; both her mother and maternal grandmother were diagnosed with the disease. So, it came as no surprise when Fathi enrolled in a study looking into the inherited [...]

Living Room Show Notes: Pulmonary Care

September 10th, 2024|Hot Topics, Newsletter Articles, Your Community|

Dr. Brian Gotkin from Memorial Physician Group joined August’s Lung Cancer Living Room to discuss the importance of having a pulmonologist on your care team. He detailed how pulmonologists contribute to early detection, screening, diagnosis, staging, therapeutics, treatment management, follow-up scans, and overall lung health. He shared that his [...]

Lung Cancer Screening: Where We Are & Where We’re Headed

September 3rd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Brittney Nichols, MPH-RN, Senior Specialist, Science and Research, Andrew Ciupek, PhD, Associate Director, Clinical Research, Courtney Granville, PhD, MSPH, Chief Scientific Officer Receiving a lung cancer diagnosis can be a scary, life-changing experience. While modern medicine has led to the development of many wonderful new lung cancer treatments, [...]

Progress and Promise in Lung Cancer Research

September 3rd, 2024|Hot Topics, Magnifying LeNS, News, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer and Roy Herbst, MD, PhD Each year, the American Society of Clinical Oncology (ASCO) holds an annual meeting that shares novel breakthroughs and transformative research in oncology. This year’s ASCO theme, “The Art and Science of Cancer [...]

Community-Engaged Research: Elevating the Patient Voice 

September 3rd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research, and Fatima Mohamed, BSc, Manager, Community Research Implementation   In the evolving landscape of healthcare research, community-engaged research (CER) is transforming the way studies are conducted and applied. Imagine a research process where the voices of community members are not just [...]

ASCO 2024 – Lung Cancer Research Takeaways

September 3rd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer  “[In the past] walking through ASCO, you were hard pressed to find anybody working in lung cancer, and now you’re hard pressed on finding somebody who is not working in lung cancer” – Danielle Hicks, Chief Patient [...]

World Conference on Lung Cancer 2024: A Preview from GO2

September 3rd, 2024|Community Engagement, Hot Topics, Science and Research|

Researchers, oncologists, pulmonologists, thoracic surgeons, and patients convene at the World Conference on Lung Cancer (WCLC) each year to discuss developments impacting the lung cancer community.   This year the International Association for the Study of Lung Cancer (IASLC)’s World Conference on Lung Cancer celebrates its 50-year anniversary in San [...]

FDA Approves New Treatment Combination for EGFR+ NSCLC

August 20th, 2024|Hot Topics, News, Science and Research|

On August 19, 2024, the U.S. Food and Drug Administration (FDA) announced their approval of an exciting new treatment combination: Rybrevant (amivantimab-vmjw) combined with Lazcluze (lazertinib). This treatment combination is meant for people who are newly diagnosed with non-small cell lung cancer (NSCLC) that is either advanced or metastatic (has [...]

FDA Approves Neoadjuvant & Adjuvant Imfinzi (durvalumab) for Resectable NSCLC

August 19th, 2024|Hot Topics, News, Science and Research|

On August 15, 2024, the U.S. Food and Drug Administration (FDA) granted approval for the immunotherapy drug Imfinzi (durvalumab) to be used in combination with chemotherapy (neoadjuvant, treatment given before surgery) as well as on its own after surgery (adjuvant). This treatment is for people who have been diagnosed with [...]

Living Room Show Notes: Best of ASCO 2024

August 12th, 2024|Hot Topics, Newsletter Articles, Science and Research, Small Cell Lung Cancer, Your Community|

The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most exciting news in the cancer field. While ASCO covers all [...]

Renee Botello, MSc: Empowering GO2’s Spanish-speaking Community

August 9th, 2024|Hot Topics, Monthly Measure, Newsletter Articles|

Meet Renee Botello, MSc, GO2 for Lung Cancer's treatment and trials navigator and one of the faces behind our HelpLine. She is also responsible for Nuestra Gente, a health education initiative that provides relevant and culturally significant information about lung cancer to Hispanic/LatinX communities in the United States. This [...]

Centers of Excellence Summit Featured Speakers: Vishisht Mehta, MD and Rodney C. Haring, PhD, MSW

August 9th, 2024|Hot Topics, Monthly Measure, Newsletter Articles|

The 2024 Center of Excellence (COE) Summit and Lung Cancer Navigator Workshop feature national and international lung cancer experts. Attendees will learn about cutting-edge technologies, emerging therapies, and the successes and challenges of program implementation.   Learn more about 2 of our speakers, who will present information critical to addressing [...]

An Evening of Excellence 

August 6th, 2024|Hot Topics, News|

Showcasing innovations and progress transforming lung cancer survivorship  On June 13, 2024, GO2 for Lung Cancer hosted an Evening of Excellence in New York City to discuss innovations and progress in lung cancer screening, treatment, and survivorship. Nearly 100 people attended the event, including board members, supporters, partners, and [...]

GO2 for Lung Cancer Honors Dr. Pasi A. Jӓnne with 2024 Bonnie J. Addario Lectureship Award 

July 26th, 2024|Hot Topics, News|

WASHINGTON, July 26, 2024 — GO2 for Lung Cancer presented Pasi A. Jӓnne, M.D, Ph.D. with the 2024 Bonnie J. Addario Lectureship Award for his commitment and dedication to research and development of therapeutic strategies for patients with epidermal growth factor receptor (EGFR) mutant lung cancer.   Jӓnne is one of [...]

Living Room Show Notes: Surgical Options

July 15th, 2024|Hot Topics, Newsletter Articles, Your Community|

With recent advancements made in thoracic oncology, the management of non-small cell lung cancer (NSCLC) is evolving rapidly. While chemotherapy, immunotherapy, targeted therapy, molecular testing, and radiotherapy continue to play a large role in the management of lung cancer, especially in later-stage treatment, surgical therapy remains an essential component [...]

Physician and Patient Groups Urge USPSTF and CMS to Update and Expand Lung Cancer Screening Eligibility and Criteria 

July 10th, 2024|Advocacy in Action, Hot Topics, News, Press Releases|

Changes could impact an additional 5 million people at higher risk for lung cancer  WASHINGTON, July 9, 2024 – In its ongoing public health partnership, GO2 for Lung Cancer, the American College of Radiology (ACR) and The Society of Thoracic Surgeons (STS) again joined together to advocate for expanded access [...]

Lori B.: I Am the Face of Lung Cancer

July 9th, 2024|Hot Topics, Monthly Measure, Newsletter Articles, Spotlights, Stories of Hope, Survivors, Women|

Lori B. calls herself a “healthy-looking” woman, but she wants people to know that looks can be deceiving.   “Everyone says ‘you look so great,’” she said. “But you can’t judge a book by its cover.”   Lori lives in Park Hills, MO, a small town where everyone knows everyone. A [...]

Why Low-Dose Lung Cancer Screening Should Be Routine

July 1st, 2024|Hot Topics, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Survivors, Women, Your Community|

Low-dose CT scans for lung cancer should be as routine as mammograms  Estela Mara Bensimon is a university professor emerita at the University of Southern California and the founder of the Center for Urban Education, whose mission is to eliminate racial inequity in higher education outcomes. Bensimon is a [...]

Change, Challenges, and Newfound Strength: Gloria’s Story

June 17th, 2024|Hot Topics, Newsletter Articles, Spotlights, Survivors, Women, Your Community|

Oprima aquí para acceder al blog en español. Gloria A. lives in Puerto Rico. She is a passionate advocate, professional engineer, and friend to many people in the lung cancer community. She is an avid supporter of the Atlanta Braves baseball team and cheers for Puerto Rican players across Major [...]

Living Room Show Notes: Is a Clinical Trial Right for You?   

June 17th, 2024|Hot Topics, Newsletter Articles, Your Community|

When people think about treatment options after receiving a lung cancer diagnosis, they often don’t think about clinical trials. In fact, many people are fearful of exploring clinical trials and may shy away from discussing them with their care team. But the reality is that for many people living [...]

Meet GO2 Volunteer Jasmine Huang, MD

June 17th, 2024|Community Engagement, Fundraisers, Hot Topics, Spotlights|

Jasmine Huang, MD, is a thoracic surgeon who focuses on thoracic oncology, particularly the surgical treatment of lung cancer. As part of her responsibilities, she performs lung resection surgeries on early-stage lung cancer patients—a pathway to a cure.   Lung cancer, if found early, can be curable. That’s a big [...]

FDA Approves Augtyro (repotrectinib) for Adults and Children with NTRK-Positive Solid Tumors

June 14th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval for Augtyro (repotrectinib) applies to people:  With locally advanced or [...]

ASCO 2024: Research Updates for the Lung Cancer Community

June 11th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every year, oncology professionals worldwide meet at the American Society of [...]

Meet Sarah McHale, the Newest Member of GO2’s Patient Support Team

June 3rd, 2024|Hot Topics, Newsletter Articles, Your Community|

We are delighted to welcome Sarah McHale, LCSW, OSW-C, to the GO2 Patient Support Team as senior manager of support programs and implementation. Sarah joins Maureen Rigney, Miranda Goff, and Michele Zeh on GO2’s HelpLine to offer one-on-one support, educational resources, referrals, and guidance on screening for people living [...]

Meet GO2’s Chief Scientific Officer, Courtney Granville, PhD, MSPH

May 30th, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer and Courtney Granville, PhD, MSPH, Chief Scientific Officer, GO2 for Lung Cancer  Earlier this year, GO2 for Lung Cancer welcomed Courtney Granville, PhD, MSPH, as our new Chief Scientific Officer (CSO). We had a chance [...]

Blood-Based Testing in Lung Cancer: What, When, and Why?

May 30th, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer and Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science and Research, GO2 for Lung Cancer  Blood-based testing has become increasingly common in cancer care. In addition to routine laboratory tests, oncologists and researchers are discovering new ways that [...]

New Clinical Trial Aims to Unlock the Origins of Lung Cancer 

May 30th, 2024|Hot Topics, Magnifying LeNS, News, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer  Although most lung cancer cases happen at an older age and are associated with a history of smoking, a growing number of people are diagnosed who do not have traditional risk factors, including younger people, people without [...]

Meet Grace: Marathoner, fundraiser, and survivor

May 28th, 2024|Community Engagement, Fundraisers, Hot Topics, Monthly Measure, Newsletter Articles, Spotlights|

An avid runner and hiker, Grace never thought she would be someone who could get lung cancer, even though her father was diagnosed with the disease. Her family was surprised at her dad’s diagnosis and shocked when her mother received her own lung cancer diagnosis shortly after. At that [...]

Centers of Excellence Summit Featured Speakers: Lidia Schapira, MD, FASCO and Timothy J. Milbrandt, MS, CTTS, LMFT

May 28th, 2024|Hot Topics, Monthly Measure, Newsletter Articles|

We are excited to introduce two special guests who will present important information at our 2024 Lung Cancer Navigator Workshop and Centers of Excellence (COE) Summit in Chicago from Sept. 30 - Oct. 2.   Lidia Schapira, MD, FASCO Lidia Schapira, MD, FASCO, is a professor of medicine [...]

Maureen Rigney: Nearly two decades helping the lung cancer community

May 28th, 2024|Hot Topics, Monthly Measure, Newsletter Articles|

Since 2005, GO2 for Lung Cancer’s Senior Director, Support Programs and Psychosocial Care, Maureen Rigney, LICSW, has guided people with lung cancer and caregivers through diagnosis, treatment, and survivorship. We talked to Rigney about how she came to GO2 and why she is so passionate about her role with [...]

Living Room Show Notes: Improving Healthcare Delivery

May 20th, 2024|Hot Topics, Newsletter Articles, Your Community|

Healthcare delivery not only impacts your experiences at your health care center but can also affect your treatment outcomes. Processes and procedures are put in place at health care facilities to attempt to standardize and regulate things like wait times, coordination of care across members of your team, and [...]

Ask the Experts: Do I Need Biomarker Testing for Early-Stage Lung Cancer?

May 20th, 2024|Hot Topics, Newsletter Articles, Your Community|

Question: I was diagnosed with early-stage lung cancer. Do I need biomarker testing? Can I benefit from a targeted therapy if a biomarker is discovered?   (Answered by Dr. Collin Blakely from the University of California, San Francisco, during his appearance at the April 25, 2024 Lung Cancer Living Room. It [...]

A Veteran’s Experience with Small Cell Lung Cancer (SCLC)

May 20th, 2024|Hot Topics, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Veterans, Your Community|

Jim Fackler lives in Lancaster, South Carolina, with his wife, Gail. He is a proud Vietnam veteran who served in the United States Navy. He enjoys golf, driving his pontoon on the lake, home improvement projects, and meeting with other veterans. Jim and his wife also love to [...]

FDA Approves Imdelltra (tarlatamab-dlle) for Extensive Stage Small Cell Lung Cancer

May 17th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results from the DeLLphi-301 trial (NCT05060016). Participants with relapsed or progressive [...]

Buddy’s Personal Miracle Drug

May 2nd, 2024|Hot Topics, Newsletter Articles, Spotlights, Survivors, Veterans, Your Community|

For people diagnosed with late-stage lung cancer, Edward “Buddy” Cutler’s story may serve as a beacon of hope, a clinical trial success story, and a reminder that statistics don’t dictate a person’s unique experience.   When Buddy was diagnosed with stage 4 (IV) non-small cell lung cancer (NSCLC) 12 years [...]

Fast-Tracking Innovation: The FDA’s Process for Approving New Cancer Therapies

May 2nd, 2024|Hot Topics, Newsletter Articles, Science and Research, Your Community|

Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  The first anti-cancer therapy, mechlorethamine, was approved in 1949. Since then, the U.S. Food and Drug Administration (FDA) has worked to ensure that new lifesaving therapies reach those who need them most.  But what does [...]

Living Room Show Notes: Small Cell Lung Cancer Treatment Landscape

April 22nd, 2024|Hot Topics, Newsletter Articles, Your Community|

Treatment options for people diagnosed or living with small cell lung cancer (SCLC) are constantly improving and expanding. In fact, there are more drugs in development right now than were developed in total over the last 50 years. Investments in SCLC are finally paying off, as new therapies represent [...]

Ask the Experts: Am I at Greater Risk for Lung Cancer Because of Genetics?

April 22nd, 2024|Hot Topics, Newsletter Articles, Science and Research, Your Community|

Question: I have a family history of lung cancer – both my mother and grandmother were diagnosed with the disease. Am I at greater risk for lung cancer because of genetics?     The role of genetics in determining someone’s lung cancer risk is not fully understood. While most cases of lung [...]

One Mother’s Story

April 22nd, 2024|Hot Topics, Newsletter Articles, Spotlights, Stories of Hope, Survivors, Women, Your Community|

Lung cancer is the leading cause of cancer-related deaths in women in the United States, taking 162 women’s lives every day. That’s approximately as many lives as breast, ovarian, and cervical cancers combined.  Caroline Blanchard was just 30 years old and pregnant with her second child when she found [...]

FDA Approves Alecensa (alectinib) Following Tumor Resection for People with Early-Stage, ALK-Positive Non-Small Cell Lung Cancer

April 19th, 2024|Hot Topics, News, Science and Research|

Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung cancer (NSCLC).  The approval is based on results from the [...]

GO2 for Lung Cancer, Dana-Farber Cancer Institute, and Addario Lung Cancer Medical Institute Announce Expansion of Landmark Patient Research on Underlying Causes of Inherited Risk of Lung Cancer

April 17th, 2024|Hot Topics, News, Press Releases, Science and Research|

Clinical Trial Aims to Unlock the Origins of Lung Cancer   WASHINGTON and BOSTON, April 17, 2024 – In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), GO2’s medical research consortium, announced a major expansion of landmark [...]

Fern Halper, Ph.D., Appointed to GO2 for Lung Cancer Board of Directors

April 15th, 2024|Hot Topics, News|

Brings background in data, AI, and analytics to help guide research collaboration and improved patient outcomes  WASHINGTON, April 15, 2024 —  GO2 for Lung Cancer (GO2) announced that the organization elected Fern Halper, Ph.D. to its board of directors. Halper is vice president and senior director of TDWI Research for advanced [...]

GO2’s 5K Walk/Run Series Welcomes the White Ribbon Project

April 9th, 2024|Community Engagement, Hot Topics, Newsletter Articles, Your Community|

We are excited to welcome the White Ribbon Project as a 2024 5K walk/run partner. Representatives from the White Ribbon Project will be on-site at our 5Ks to share their important mission and distribute white ribbons to community members who would like to help raise awareness about the disease. We [...]

2024 Lung Cancer Support Group Facilitator Awardee, Christine Conti

March 25th, 2024|Hot Topics, News, Newsletter Articles, Your Community|

Congratulations to our 2024 Lung Cancer Support Group Facilitator award recipient, Christine Conti, from Huntington Health in Pasadena, California. This award, given annually since 2009, recognizes the uncommon dedication of support group facilitators. Christine Conti, RN, ONN-CG, is a thoracic nurse navigator who has been Huntington Health’s lung cancer support [...]

2024 Lung Cancer Voices Summit Recap

March 19th, 2024|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles|

GO2 for Lung Cancer’s Voices Summit is the only annual meeting that brings the lung cancer community together for education, training, connection, and advocacy action with our federal government, the largest funder of cancer research.   This month, nearly 200 advocates from 31 states gathered in Washington, D.C., for the [...]

Mary’s Lung Cancer Story: It Doesn’t Stop You From Living

March 11th, 2024|Hot Topics, Newsletter Articles, Spotlights, Survivors, Women, Your Community|

For people diagnosed with lung cancer, receiving a second opinion can be an important step in confirming treatment decisions or opting for a new approach to treatment.   In Mary Burlie’s case, getting a second opinion changed everything. Although her first oncologist did not believe that Mary’s lung cancer had [...]

FDA Approves Rybrevant (amivantamab-vmjw) for Non-small Cell Lung Cancer with EGFR-Exon 20 Mutation

March 4th, 2024|Hot Topics, News|

On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved the drug Rybrevant (amivantamab-vmjw) to be given in combination with carboplatin and pemetrexed in the first lining setting for people with metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 mutation. They also announced traditional approval [...]

GO2 for Lung Cancer Holds Lung Cancer Voices Summit on Capitol Hill to Advocate for Increased Research Funding for the Leading Cause of Cancer Death

March 4th, 2024|Advocacy in Action, Hot Topics, News, Press Releases|

More than 230,000 Americans will die of lung cancer this year WASHINGTON, March 4, 2024 - On Tuesday, March 5 GO2 for Lung Cancer (GO2) will host more than 200 supporters on Capitol Hill to educate members of Congress on the urgent needs of the lung cancer community. GO2’s Lung Cancer [...]

Meet HealthUnlocked’s “Denzie:” Celebrating 13 Years of Survival

February 27th, 2024|Hot Topics, Spotlights, Stories of Hope, Survivors, Women|

If you have spent any time in GO2’s online support community, HealthUnlocked, you have likely come across posts, advice or support from a member who calls herself “Denzie.” Denzie volunteers as a dedicated moderator, welcomes new users, answers questions and provides encouragement and comradery to [...]

Ask the Experts: What’s New in SCLC Research?  

February 26th, 2024|Hot Topics, Newsletter Articles, Your Community|

Question: I have small cell lung cancer (SCLC). What’s new in research related to SCLC? What should I know about clinical trials?  (Answered by Dr. Jacob Sands from Dana-Farber Cancer Institute during his appearance on the Lung Cancer Living Room. It has been edited slightly for this use.)   Answer: [...]

Finding Hope in an ALK+ Diagnosis

February 26th, 2024|Hot Topics, Newsletter Articles, Spotlights, Stories of Hope, Survivors, Your Community|

Craig S. lives in Washington, D.C., with his wife, Lydia, and daughter, Lola, who is a freshman at Tulane University. He has worked in software sales and sales leadership since getting his MBA from George Washington University. He enjoys rooting for the Washington Nationals, cooking, [...]

Do I Need Another Test? The Importance of Repeat Biomarker Testing in NSCLC

February 22nd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles|

Author: Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science & Research, GO2 for Lung Cancer Biomarker testing is an important part of the cancer diagnosis and care continuum. For almost all people diagnosed with non-small cell lung cancer (NSCLC) biomarker testing is considered a routine part of guideline-concordant care (the [...]

Unleashing Precision: AI’s Promising Role in Revolutionizing Lung Cancer Care

February 22nd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer You’ve likely started to see artificial intelligence (AI) being used more and more in your everyday life. While the benefits and challenges of using AI in fields such as healthcare must be carefully considered, we [...]

Antibody-Drug Conjugates (ADCs): A Promising Treatment for Lung Cancer

February 22nd, 2024|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer With decades of research and advances in precision medicine, scientists continue to broaden the treatment standards and options for patients with non-small cell lung cancer (NSCLC). By developing new ways, strategies, and innovative research techniques, this rapid [...]

Nicole Phipps Is Spearheading GO2’s Efforts to Confront Lung Cancer Every Day for Everyone 

February 21st, 2024|Hot Topics, Monthly Measure, Newsletter Articles|

Nicole Phipps took a job working in lung cancer advocacy almost thirteen years ago to honor her grandfather, a lung cancer survivor. Now she’s applying that passion—and her considerable skills—to ensure that vital lung cancer education, support, connection, and community are accessible to all.   Meet [...]

FDA Approves Tepmetko (tepotinib) for People with Metastatic Non-Small Cell Lung Cancer with MET-Exon 14 Mutation

February 16th, 2024|Hot Topics, News|

On Feb. 15, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation. Tepmetko (tepotinib) initially received accelerated approval in 2021 based on initial results from the VISION study, which [...]

Lung Cancer is the Leading Cause of Cancer Death in Women—GO2 for Lung Cancer President & CEO Provides Testimony as Part of the “Legislative Proposals to Support Patients and Caregivers” Hearing

February 16th, 2024|Advocacy in Action, Hot Topics, News, Press Releases|

WASHINGTON, Feb. 16, 2023—GO2 for Lung Cancer President and CEO Laurie Ambrose submitted testimony to the House Committee on Energy and Commerce, Subcommittee on Health. Ambrose’s testimony was in support of the Women and Lung Cancer Research & Preventive Services Act of 2023, introduced in the House by Congressman [...]

GO2 for Lung Cancer Appoints Courtney Granville, Ph.D., M.S.P.H. as Chief Scientific Officer

February 12th, 2024|Hot Topics, News, Press Releases|

Granville brings experience overseeing scientific strategy and research  WASHINGTON, Feb. 12, 2024 — GO2 for Lung Cancer (GO2) announced that it has hired Courtney Granville as chief scientific officer. In this role, she oversees GO2’s community-engaged research, clinical research, Lung Cancer Registry, and LungMATCH programs. She develops and manages the implementation [...]

Faith, Family, and a Groundbreaking Trial

February 12th, 2024|Hot Topics, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Survivors, Women, Your Community|

Aundrea H. is a married mother of three who lives in Washington state, where she homeschools her children (ages 17, 15, and 12). She enjoys spending time with her family and friends as well as being involved in church activities.   My diagnosis  In December 2023, I was recovering [...]

Living Room Show Notes: What To Do if Resistance Develops

February 12th, 2024|Hot Topics, Newsletter Articles, Your Community|

Many people being treated for lung cancer will eventually develop resistance to their current therapies, causing them to stop working. When this happens, and a person’s cancer starts to progress on their current treatment, their healthcare team will take a tissue and/or liquid biopsy to access their new treatment [...]

GO2 Joins National Leaders Calling on the White House to Expand Women’s Health Research and Funding

January 30th, 2024|Advocacy in Action, Hot Topics, News|

GO2 for Lung Cancer joined a diverse group of women’s health champions by signing two letters sent to First Lady Jill Biden, who leads the White House Initiative on Women’s Health Research. The letters offer insights and recommendations on opportunities to fundamentally change approaches to increased health research and [...]

Meet the Honorees: 18th Annual Simply the Best Gala 

January 23rd, 2024|Hot Topics, Monthly Measure, Newsletter Articles|

For the past 18 years, we have held our Simply the Best Gala with survivors, loved ones, providers, researchers, and industry partners, to celebrate and honor outstanding members of the lung cancer community.  “We are grateful to the many dedicated individuals that bring tangible hope to people at risk [...]

Adedayo Adeniyi: Making an Impact One Policy at a Time

January 23rd, 2024|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles|

Adedayo Adeniyi was drawn to public health advocacy because he knows how one piece of legislation can change the lives of many.   Adedayo, who has a degree in public health and a master’s in public policy, is GO2 for Lung Cancer’s government affairs manager, where he is responsible for [...]

Ask the Experts: Insurance Coverage for Lung Cancer Treatment

January 17th, 2024|Hot Topics, Newsletter Articles, Your Community|

Question: My insurance does not cover the cost of my lung cancer treatment. What are my options?   Answer: When insurance does not cover the cost of lung cancer drug treatments, there are a few options to explore for financial assistance.   Get to know your insurance: We know dealing with [...]

Ask the Experts: Nutrition During Treatment

December 18th, 2023|Hot Topics, Newsletter Articles, Your Community|

Answered by Michele Szafranksi, MS, RD, CSO, LDN, Clinical Nutrition Manager, Section of Oncology Nutrition, Department of Supportive Oncology, Levine Cancer Institute  Question: I was diagnosed with lung cancer a few weeks ago and am about to start treatment. What role can nutrition play in helping me to feel [...]

Living Room Show Notes: Lung Cancer Awareness Month (LCAM) Edition

December 18th, 2023|Hot Topics, Newsletter Articles, Your Community|

During November for Lung Cancer Awareness Month (LCAM), GO2 for Lung Cancer and the LCAM Coalition hosted a special Lung Cancer Living Room to discuss stigma. The LCAM Coalition raises awareness about lung cancer and the need for more research, screening, and treatment options to improve survival.   Lung [...]

Treatments and Study Updates: Highlights from ESMO 2023 

December 4th, 2023|Hot Topics, Newsletter Articles, Science and Research, Your Community|

Contributing Authors: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD and Manager, Precision Medicine & Navigation, Matthew Reiss, MSE, PhD   Each year, researchers, physicians, and industry partners gather at the European Society for Medical Oncology (ESMO) Congress to share the latest updates on new treatments [...]

Sydney Barned Wants You to Join Her at the Lung Cancer Voices Summit

December 4th, 2023|Advocacy in Action, Hot Topics, Newsletter Articles, Your Community|

Sydney Barned, MD, has marked the date on her calendar: March 3–5, 2024. That’s when lung cancer advocates nationwide will unite in D.C. for GO2’s next Lung Cancer Voices Summit. She’s passionate about advocacy and wants more people, especially younger women, to join her in [...]

Living Room Show Notes: Medical and Radiation Oncologists

November 20th, 2023|Hot Topics, Newsletter Articles, Your Community|

Medical and radiation oncologists are important members of your lung cancer care team who work together with you to determine your treatment plan and deliver your care. Drs. Jonathan Riess and Megan Daly from UC Davis’s Comprehensive Cancer Center joined GO2’s October Lung Cancer Living Room to discuss the [...]

GO2 for Lung Cancer Celebrates the Lung Cancer Community at the 18th Annual Simply the Best Gala

November 17th, 2023|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON (November 13, 2023) – GO2 for Lung Cancer (GO2) honored champions of lung cancer at its 18th Annual Simply the Best Gala held in San Francisco on November 11. This special evening was an opportunity to recognize industry partners, researchers, doctors, nurses, survivors, funders, and individual supporters [...]

FDA Approves Augtyro (repotrectinib) for People with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

November 16th, 2023|Hot Topics, Science and Research|

On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from the TRIDENT-1 study, which evaluated the use of Augtyro (repotrectinib) [...]

Heather Law Is Looking to Crack the Code on Lung Cancer 

November 15th, 2023|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

Seeking insights from the causes of lung cancer to support for family caregivers  Heather Law, MA, is seeking answers. She wants to understand why some people get lung cancer and others don’t. She’s anxious to learn how treatments change over time and what improves a person’s quality of life. [...]

Cliff Norton Brings Hope, Determination to Lung Cancer Advocacy 

November 15th, 2023|Hot Topics, Monthly Measure, Newsletter Articles, Spotlights, Survivors|

When Cliff Norton walks into a room, he brings hope through the door with him. Diagnosed with stage 4 (IV) lung cancer in July 2010, he was declared NED (no evidence of disease) in December 2012. More than a decade and many PET scans later, he’s still cancer-free.   His [...]

Rick Sherlock Brings a Life of Service to the Lung Cancer Community  

November 15th, 2023|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles|

Rick Sherlock has spent his life in service to others. The retired army major general has flown Chinooks, Blackhawks, and other aircraft. He has served his country at home and abroad, including tours of duty in South Korea, Iraq, and Germany, as well as several tours of duty at [...]

Groundbreaking Research on Inherited Gene Mutation in Lung Cancer Published in Journal of Clinical Oncology

November 13th, 2023|News|

GO2 for Lung Cancer announced that researchers have described a new familial syndrome in people with lung cancer caused by an inherited gene mutation. The research study was published this month in the Journal of Clinical Oncology. The report chronicles the methods and findings of the INHERIT study, more than [...]

GO2 for Lung Cancer Launches PSA Featuring Actor and Director Tony Goldwyn for National Lung Cancer Awareness Month in November

November 1st, 2023|Hot Topics, News, Press Releases|

Goldwyn has a personal connection to lung cancer  WASHINGTON, November 1, 2023—  GO2 for Lung Cancer, is launching a public service announcement campaign starting the first of November in conjunction with National Lung Cancer Awareness Month. The PSA features acclaimed actor, producer and director Tony Goldwyn, recently seen in the blockbuster [...]

Presidential Proclamation Designates November 2023 as National Lung Cancer Awareness Month

October 31st, 2023|Hot Topics, News|

As we come together on the eve of Lung Cancer Awareness Month, we are excited to share that President and First Lady Biden have joined us again to bring much-needed attention to this disease by issuing a Presidential Proclamation designating November 2023 as National Lung Cancer Awareness Month. As in [...]

Treatments, Trials, and Technology in Lung Cancer

October 23rd, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung cancer treatment and research. New treatment options on the horizon [...]

New Clinical Trial Designs in the Era of Precision Medicine

October 23rd, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD With an increasing number of targeted therapies becoming available, making treatment decisions based on the results of biomarker testing has become an essential part of cancer care – especially in lung cancer. At the same time, researchers [...]

Addressing the Unmet Needs of Family Caregivers of People with Lung Cancer  

October 23rd, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Lung Cancer Registry Associate Director, Heather Law, MA  Family caregivers often experience emotional distress and neglect their own well-being while caring for a loved one. Preliminary findings from GO2’s Lung Cancer Registry Caregiver Survey were presented at the 2023 World Conference on Lung Cancer (WCLC) in Singapore in September.  Understanding the unmet need  Advances in diagnostic [...]

Perspectives from Providers, Patient Advocates, and People Living with Lung Cancer

October 23rd, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: GO2 for Lung Cancer's Specialist, Science & Research, Brittney Nichols MPH, BSN-RN The IASLC annual World Conference on Lung Cancer (WCLC) unites lung cancer professionals from across the world to connect and share insights. This goes beyond the science and medicine of treating and diagnosing lung cancer—it expands [...]

Lung Cancer After Tagrisso Resistance: What Next?

October 23rd, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: GO2 for Lung Cancer Treatment and Trials Navigator, Renee Botello MSc Tagrisso (osimertinib) has been the treatment of choice and effective standard of care option for the treatment of EGFR+ non-small cell lung cancer (NSCLC) since its FDA approval in 2018 as a first-line treatment for EGFR+ NSCLC. [...]

ASCO Issues New Recommendation Cosela (Trilaciclib) in Update to its Treatment Guidelines for Small Cell Lung Cancer

October 20th, 2023|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who are receiving treatment with chemotherapy or chemoimmunotherapy. Myelosuppression or bone [...]

FDA Approves New Treatment Regimen for Individuals Receiving Keytruda (pembrolizumab) for Resectable Non-Small Cell Lung Cancer

October 18th, 2023|Hot Topics, News, Science and Research|

On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical trial that assessed a new treatment plan for persons with [...]

FDA Approves Combination Braftovi (encorafenib) and Mektovi (binimetinib) for Metastatic BRAF-Mutated Non-Small Cell Lung Cancer

October 18th, 2023|Hot Topics, News, Science and Research|

On October 11, 2023, the U.S. Food and Drug Administration (FDA) approved a combination of Braftovi (encorafenib) and Mektovi (binimetinib) for people with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. BRAF is a less common genetic mutation, affecting 1-2% of individuals diagnosed with NSCLC, and [...]

Living Room Show Notes: What’s New in Pulmonary Care

October 17th, 2023|Hot Topics, Newsletter Articles, Your Community|

“If you can’t breathe, nothing else matters.” This powerful statement was shared by Dr. D. Kyle Hogarth from the University of Chicago during September’s Lung Cancer Living Room to emphasize the importance of having a pulmonologist on your lung cancer care team. A pulmonologist is a medical professional who [...]

Ask the Experts: I’m Worried About Bothering My Doctor. What Should I Do?

October 17th, 2023|Hot Topics, Newsletter Articles, Your Community|

Question: I have many questions about my lung cancer diagnosis and treatment options, but I’m worried about bothering my doctor. What should I do?  Answer:* If you have an oncologist who makes you feel like you shouldn’t be contacting them, then you have the wrong oncologist. What will keep me [...]

Finding Strength After a Small Cell Lung Cancer Diagnosis: Bob’s Story

October 3rd, 2023|Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Stories of Hope, Your Community|

After spending over 20 years in the hospitality field, Bob Iles changed careers and joined the stock brokerage industry before retiring almost six years ago. He and his husband live in Palm Springs, CA, where he enjoys swimming in his lap pool, hiking, biking, volunteering for environmental and LGBTQ+ [...]

Ask the Experts: Neo-Adjuvant vs. Adjuvant Therapy

October 2nd, 2023|Hot Topics, Newsletter Articles, Your Community|

Question: What is the difference between neo-adjuvant therapy and adjuvant therapy? Answer: “Neo-adjuvant” and “adjuvant” are terms used in the context of cancer treatment to refer to therapies that are given before or after the primary treatment, such as surgery or radiation therapy. Neo-adjuvant therapy refers to treatment given before [...]

Support for Small Cell Lung Cancer

October 2nd, 2023|Hot Topics, Newsletter Articles, Your Community|

GO2 for Lung Cancer’s Small Cell Lung Cancer (SCLC) program offers education, support, and connection to those affected by SCLC. People living with SCLC often have different needs than those with non-small cell lung cancer (NSCLC). Our SCLC program aims to better meet those needs by expanding our SCLC-specific resources, [...]

Top Treatment Takeaways from the World Conference on Lung Cancer

September 27th, 2023|Hot Topics, Science and Research, Small Cell Lung Cancer|

Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s work as well as learning about the latest treatment updates.   [...]

A New Lease on Life: Mike’s Story

September 15th, 2023|Hot Topics, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Stories of Hope, Survivors, Your Community|

By Mike Knecht   Mike Knecht retired from his career as an electrical contractor and business owner in 2019 and spent the following year traveling through the United States and Africa. In early 2023, he and his wife, Lois, sold their home in Maryland to live full-time in their vacation/retirement home in West Virginia. Mike enjoys a wide variety of activities from hobby farming on his 150-acre mountain-top property, to visiting his daughters and grandchildren on both [...]

Scanxiety: Tips from a Survivor and Expert

September 14th, 2023|Hot Topics, Newsletter Articles, Your Community|

By Alison Mayer Sachs, MSW, LSW, OSW-C, FAOSW, Director, Community Outreach & Cancer Support, Services, Eisenhower Lucy Curci Cancer Center, Eisenhower Medical Center and lung cancer survivor “Scanxiety” is a term that people with cancer use to describe the anxiousness and fear they experience before, during, and after scans to [...]

Processing Trauma After a Lung Cancer Diagnosis

September 5th, 2023|Hot Topics, Newsletter Articles, Stories of Hope, Your Community|

By Susan Smedley Susan Smedley is a 25-year lung cancer survivor and former social worker who worked in the national lung cancer community for 15 years, most recently at GO2 for Lung Cancer. As a yoga instructor trained in oncology and trauma-informed yoga, she retired from nonprofit work to [...]

Stronger Together: GO2 for Lung Cancer and KRAS Kickers

August 17th, 2023|Hot Topics, Newsletter Articles, Your Community|

GO2’s Phone Buddy Program, first launched in the 1990s, is a peer-to-peer matching program that pairs people who have been diagnosed with lung cancer to share stories, hope, and wisdom with one another.   As a GO2 Phone Buddy herself, Terri Conneran, founder of KRAS Kickers, knows the value of bringing [...]

Ask the Experts: Clinical Trials for KRAS+ Lung Cancer

August 17th, 2023|Hot Topics, Newsletter Articles, Your Community|

Question: I have KRAS+ lung cancer. Are there any clinical trials available for me?   Answer: Yes! No matter what kind of lung cancer you are diagnosed with, there is likely a trial appropriate for you.   GO2 for Lung Cancer has our own KRAS study — launched with our medical research consortium, [...]

Meet GO2’s New National Ambassador Council Members

August 17th, 2023|Hot Topics, Newsletter Articles, Your Community|

Bob Nicklas, nine (9) year lung cancer survivor and GO2 NAC member Two new advocates joined GO2 for Lung Cancer’s National Ambassador Council (NAC) and participated in their first meeting last month.   Bob Nicklas joins NAC after receiving GO2’s 2022 Voices Summit Leadership & Advocacy Award, serving [...]

Living Room Show Notes: Best of ASCO 2023

August 3rd, 2023|Hot Topics, Newsletter Articles, Science and Research, Your Community|

The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on emerging science in the cancer field. While ASCO covers all [...]

GO2 for Lung Cancer Honors David Carbone, MD, PhD with the 2023 Bonnie J. Addario Lectureship Award

July 28th, 2023|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON, D.C. (July 28, 2023) – GO2 for Lung Cancer (GO2) announced today that it presented David Carbone, MD, PhD with the 2023 Bonnie J. Addario Lectureship Award for his work developing treatments for lung cancer. GO2 honored Dr. Carbone with the award at the 24th International Lung Cancer Conference [...]

ASCO 2023: Surviving and Thriving with Lung Cancer 

July 25th, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Brittney Nichols, MPH, RN-BSN, Science and Research Specialist, GO2 for Lung Cancer  New treatments, developments, and scientific breakthroughs are always one of the most exciting aspects of the annual American Society of Clinical Oncology (ASCO) conference, but this year they weren't the only highlight. People with lung cancer, [...]

ASCO 2023: Progress for Metastatic (Stage 4) Non-Small Cell Lung Cancer

July 25th, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from several studies was shared, including new developments for both people [...]

ASCO 2023: Advances in Early-Stage Lung Cancer Research

July 25th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer  While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has spread) and not used for earlier stages. We are now [...]

ASCO 2023: New Advances in Lung Cancer Screening

July 25th, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles|

By Heather Law, MA, Associate Director, GO2’s Lung Cancer Registry  Lung cancer screening is unavailable for many people at risk for lung cancer. At the 2023 American Society of Clinical Oncology (ASCO) meeting, early results from groundbreaking studies offered hope for expanded screening in the United States.   Current [...]

Hope and Time: Tamara’s Story 

July 24th, 2023|Advocacy in Action, Hot Topics, Newsletter Articles, Stories of Hope, Your Community|

By Tamara Gabrielli, MD   Dr. Gabrielli recently retired after a 30-year career as an anesthesiologist in Maryland and Washington, D.C. She lives in Rockville, MD and has three daughters in their 20s. She just celebrated her 64th birthday.   My diagnosis   I was diagnosed with lung cancer about 16 [...]

Living Room Show Notes: Special Edition – Early Detection, Treatment, and Access to Care

July 24th, 2023|Hot Topics, Newsletter Articles, Your Community|

In a Special Edition Lung Cancer Living Room that aired on June 6, 2023, Dr. Steven Liu from Georgetown University shared an introduction to lung cancer, plus an overview of its history including staging diagnosis. In clear, easy-to-understand language, he detailed the most up-to-date information about treatment options, including [...]

Living Room Show Notes: Clinical Trials and Innovative Trial Design

July 13th, 2023|Hot Topics, Newsletter Articles, Your Community|

Clinical trials are a critical part of developing future treatments for lung cancer and other diseases, but low enrollment indicates that they are also often misunderstood by people who might benefit from them.   In June’s Lung Cancer Living Room, GO2 for Lung Cancer’s Chief Patient Officer, Danielle Hicks, was [...]

Legislation Introduced to Accelerate Life-Saving Change for Women Impacted by Lung Cancer

July 12th, 2023|Advocacy in Action, Hot Topics, News, Press Releases|

The Women and Lung Cancer Research and Preventive Service Act Will Expand Resources to Understand the Science of Lung Cancer in Women San Carlos, CA and Washington, DC – Today, GO2 for Lung Cancer (GO2) applauded the efforts of a bipartisan and bicameral group of lawmakers to address the [...]

Ask the Experts: The Importance of Multidisciplinary Care Teams

June 14th, 2023|Hot Topics, Newsletter Articles, Your Community|

Question: I keep hearing about the importance of having a multidisciplinary care team for my lung cancer treatments. What does “multidisciplinary care team” mean and who might be on it? Answer: A “multidisciplinary care team” is a group of doctors, nurses, and other healthcare professionals from different fields who [...]

Remembering Lung Cancer Champion Win Boerckel

May 30th, 2023|Advocacy in Action, Hot Topics, Newsletter Articles, Your Community|

By GO2 Senior Director, Support Initiatives, Maureen Rigney, LICSW  Win Boerckel receiving GO2’s inaugural Lung Cancer Support Group Facilitator Award in 2009 Treasured GO2 friend and staunch lung cancer advocate, Winfield Boerckel, died in May following a diagnosis of brain cancer. Some of you may have had [...]

Our 2023 Volunteer Leadership & Advocacy Award Winner: Heidi Nafman-Onda

May 30th, 2023|Advocacy in Action, Hot Topics, Newsletter Articles, Your Community|

We are excited to announce that our 2023 Volunteer Leadership & Advocacy Award winner is Heidi Nafman-Onda! This award honors a member of the lung cancer community for their outstanding leadership in volunteerism and advocacy and is awarded annually at GO2’s Lung Cancer Voices Summit.   Heidi was a fitness trainer [...]

Living Room Show Notes: The Next Wave of Precision Medicine   

May 12th, 2023|Hot Topics, Newsletter Articles, Your Community|

Treatment for lung cancer has advanced considerably over the years and has been accelerating at an even faster rate this past decade. People diagnosed with lung cancer today have newer, more personalized treatment options that may include targeted therapies, immunotherapies, combination therapies and more traditional chemotherapies or radiation. The [...]

Our 2023 Lung Cancer Support Group Facilitator Awardees 

April 27th, 2023|Hot Topics, Newsletter Articles, Your Community|

GO2's Senior Manager of Support Services, Miranda Goff; award recipients Michelle Hills and Sarah Bechard; GO2's Senior Director of Support Initiatives, Maureen Rigney We are excited to announce our 2023 Lung Cancer Support Group Facilitator awardees are Sarah Bechard and Michelle Hills. Awarded annually since 2009, [...]

Living Room Show Notes: The Vital Patient Role in Advancing Research

April 11th, 2023|Advocacy in Action, Hot Topics, Newsletter Articles, Your Community|

An important development in lung cancer research over the past decade or so is the increased prioritization of the patient experience in the research process. Including patient voices in lung cancer research helps to ensure that new research projects best meet the needs of lung cancer patients and survivors.   [...]

U.S. House of Representatives Introduces Bill to Expand Number of Cancers Detected by Screening

April 5th, 2023|Advocacy in Action, Hot Topics, News|

The Nancy Gardner Sewell Medicare Multi Cancer Early Detection Screening Coverage Act creates a path forward for Medicare coverage of multi-cancer early detection tests WASHINGTON, D.C. – GO2 for Lung Cancer (GO2) applauds Representatives Jodey Arrington, (R-TX), Terri Sewell (D-AL), Richard Hudson (R-NC), and Raul Ruiz (D-CA) for introducing a [...]

We Walk This Path Together: Jan Maharam and Irene Stempler‘s Phone Buddy Friendship

March 2nd, 2023|Hot Topics, Newsletter Articles, Stories of Hope, Your Community|

GO2 for Lung Cancer's Phone Buddy program began in the early 1990s. Thanks to the many volunteers who give their time to speak with others about their own lung cancer experience, it is still going strong today. The program connects people diagnosed with lung cancer and their loved ones [...]

Advocating for Equitable Access to Comprehensive Biomarker Testing

February 16th, 2023|Advocacy in Action, Hot Topics, Newsletter Articles, Your Community|

GO2 for Lung Cancer, in partnership with the American Cancer Society Cancer Action Network (ACS CAN) and other health advocacy groups, is supporting a campaign to reduce health disparities by working to ensure equitable access to comprehensive biomarker testing. This campaign aims to improve coverage for and access to [...]

New Study to Understand Why Cancers Progress After Using KRAS Inhibitors

February 9th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Jennifer C. King, PhD, Chief Scientific Officer GO2 for Lung Cancer has launched the SPARK Study to help understand cancer driven by changes in the KRAS gene. This study is through our medical research consortium, ALCMI (Addario Lung Cancer Medical Institute), in collaboration with Dr. Mark Award and [...]

A Year of Growth for GO2 Research

February 9th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director of Clinical Research; Heather Law, MA, Associate Director of Lung Cancer Registry; Shanada Monestime, PharmD, BCOP, Director of Community Engaged Research; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program  2022 was an exciting year for GO2 for Lung Cancer. We had the privilege [...]

FDA Approvals: New Treatment Landscape in 2023

February 9th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This included targeting mutations that were previously unavailable for patients as [...]

FDA Approves Keytruda after Surgery and Chemotherapy for Early Stage Lung Cancers

January 27th, 2023|Hot Topics, News, Science and Research|

On January 26, 2023, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC).  This approval was based on the KEYNOTE-091 clinical trial where people who took Keytruda after surgery [...]

Gone but Not Forgotten: How Kimberly Goodloe Honors Her Sister by Raising Awareness

January 19th, 2023|Hot Topics, Newsletter Articles, Spotlights, Women, Your Community|

Kimberly Goodloe didn’t decide to become an advocate - she was called to it after heartache and tragedy struck her life in 2009, and then again in 2022.  In 2009, Kimberly received urgent open-heart surgery for an abnormal heart valve.  She was born with the defect but was unaware [...]

FDA Approves Krazati for Lung Cancer with a KRAS G12C Mutation

December 13th, 2022|Hot Topics, News, Science and Research|

On December 12th, 2022, the Food and Drug Administration (FDA) approved Krazati (adagrasib) for treatment of non-small cell lung cancer (nsclc) where there is a KRAS G12C mutation. This approval is for patients who have received at least one line of prior treatment such as chemotherapy. The FDA based their [...]

Ask the Experts: Lung Cancer and Family History

December 7th, 2022|Hot Topics|

Question: I have a family history of lung cancer – both my mother and grandmother were diagnosed with the disease. Am I at greater risk for lung cancer because of genetics?    The role that genetics plays in determining someone’s lung cancer risk is not fully understood. While most [...]

Hundreds of Health Facilities Hosted “Shine A Light on Lung Cancer” Events in November for Lung Cancer Awareness Month

December 1st, 2022|Community Engagement, Hot Topics, News, Press Releases|

Events brought together patients, health providers and caregivers for hope and healing. SAN CARLOS, CA and WASHINGTON, Nov. 30, 2022 – During November hundreds of health facilities hosted Shine A Light on Lung Cancer events – which made it the largest coordinated lung cancer awareness program in the country. It was the [...]

New Study to Address Cancer Treatment Resistance for People Who Are KRAS Positive

November 30th, 2022|Hot Topics, News, Science and Research|

SAN CARLOS, Calif., (November 30, 2022) – The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and other cancer types. ALCMI is partnering on the study with [...]

Ask the Experts: Biomarkers and Biopsies

November 22nd, 2022|Hot Topics|

Question: My doctors have determined that my lung cancer is progressing on its current targeted therapy and want to do another biopsy. Why would I need another biopsy since we already know the biomarker type? If I do need another biopsy, should I consider a tissue biopsy or a [...]

Survivor Spotlight: Heidi Hanson on Finding Your Strength and Living in the Moment

November 22nd, 2022|Hot Topics, Small Cell Lung Cancer Spotlight, Spotlights, Survivors, Women|

When Heidi Hanson was diagnosed with stage 4 metastatic small cell lung cancer (SCLC) in December 2021, it wasn’t the typical story. Heidi had been suffering from headaches and dizziness which sent her to the emergency room. It was there that she was told surgery was needed to remove [...]

FDA Approves Imjudo and Imfinzi in Combination with Chemotherapy for Patients with NSCLC

November 14th, 2022|Hot Topics, News, Science and Research|

On November 10th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA based their approval on the results of the clinical trial [...]

Living Room Show Notes – Understanding Lung Nodules

November 10th, 2022|Hot Topics|

Author: Danielle Hicks, Chief Patient Officer Discovering that you have a lung nodule can be understandably scary. While they are common and can lead to lung cancer, most are not cancerous. According to October’s Living Room speaker Dr. Anthony Lanfranco from the University of Pennsylvania, even those that do [...]

FDA Approves Libtayo in Combination with Chemotherapy for Patients with NSCLC Regardless of PD-L1 Status

November 9th, 2022|Hot Topics, News, Science and Research|

On November 8th, 2022, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for treatment of non-small cell lung cancer where there are no changes in ALK, EGFR or ROS1 in combination with platinum doublet chemotherapy. The FDA based their approval on the results of the clinical trial Study [...]

The WHAM Report: Investing Just $40 Million New Dollars in Lung Cancer Research Related to Women Has Dramatic Impact on U.S. Economy

November 1st, 2022|Hot Topics, News, Press Releases|

Lung cancer kills more women in the U.S. than breast, ovarian and cervical cancers combined. The report commissioned by Women’s Health Access Matters (WHAM) is based on novel microsimulation modeling from the RAND Corporation and documentation consistent with previous analyses on women and Alzheimer’s, coronary artery disease and rheumatoid [...]

GO2 for Lung Cancer Honors Key Partner in Fight Against Lung Cancer

October 31st, 2022|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON – GO2 for Lung Cancer (GO2 for Lung Cancer) announced it will honor Daiichi Sankyo with the “Simply the Best Award” for their commitment to advancing lung cancer oncology discovery to meet the needs of all patients. The company will accept the award at the Simply [...]

Presidential Proclamation Designates November as National Lung Cancer Awareness Month

October 31st, 2022|Advocacy in Action, Hot Topics, News|

As we come together to commemorate Lung Cancer Awareness Month, we are excited to share that President and First Lady Biden who just issued a Presidential Proclamation designating November 2022 as National Lung Cancer Awareness Month! GO2 is honored to have partnered with the White House in developing this [...]

Advances in Precision Medicine for Late Stage Lung Cancer

October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Authors: Renee Botello, MSc., Treatment and Trials Navigator; Andrew Ciupek, PhD, Associate Director, Clinical Research; Chief Scientific Officer Jennifer C. King, PhD; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research Every person’s cancer is different, which is why we cannot use a one-size-fits-all approach to treatment. Precision medicine uses [...]

GO2 for Lung Cancer’s Presence at The World Conference on Lung Cancer 2022

October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Brittney Nichols, MPH, BSN-RN, Specialist, Science and Research This summer, the World Conference on Lung Cancer convened in Vienna, Austria. GO2 shared our research with this community as both lead authors and collaborators on several projects to help advance the diagnosis, treatment, and survival of people with lung [...]

Advances in Treatment for Early Stage Non-Small Cell Lung Cancer

October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, like with metastatic NSCLC, the treatment landscape for patients with [...]

Jennifer Moran on Finding Inspiration – and Inspiring Others

October 24th, 2022|Hot Topics, Science and Research|

Participating in research offers her hope of changing the course of lung cancer Jennifer Moran is married to her high school sweetheart. They have two teenage children in college. A photography major who once dreamed of working at National Geographic, she fell into “a wonderful career in ophthalmic photography.” [...]

GO2 for Lung Cancer’s Kathy Levy a Finalist for Prestigious Catalyst for Equity Award

October 20th, 2022|Hot Topics, News|

We’re delighted to announce that Kathy Levy, GO2 for Lung Cancer’s ALCASE Project Manager, was a finalist for the prestigious C2 Catalyst for Equity award. The award recognizes people who have worked to overcome longstanding racial and ethnic disparities in cancer care, ensuring that all people have equitable access [...]

Living Room Recap – Options and Next Steps If Your Lung Cancer Becomes Resistant to Your Course of Treatment

October 13th, 2022|Hot Topics, Science and Research|

What happens when your cancer becomes resistant to your course of treatment and progresses? That’s the question we explored in the September episode of our Lung Cancer Living Room series. Dr. David Gandara, professor emeritus and co-director of UC Davis Comprehensive Cancer Center’s Center for Experimental Therapeutics, discussed a [...]

Highlights from the World Conference on Lung Cancer

September 23rd, 2022|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research; Jennifer C. King, PhD, Chief Scientific Officer; Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Doctors and scientists from around the world who are passionate about lung cancer convened last month to bring us the latest on the treatment landscape. GO2 [...]

GO2 for Lung Cancer Receives Grant Award from Disabled Veterans National Foundation

September 17th, 2022|Hot Topics, News, Press Releases|

Media Contact: Lori Millner Chief Marketing Officer lmillner@go2.org FOR IMMEDIATE RELEASE: Washington D.C. – September 15, 2022 GO2 for Lung Cancer is honored to announce it received a $25,000 grant from the Disabled Veterans National Foundation (DVNF). The grant will help fund its “Partners and Progress” program which works [...]

Living Room Recap – Reasons to be Optimistic About Small Cell Lung Cancer (SCLC) 

August 31st, 2022|Hot Topics, Small Cell Lung Cancer|

Small cell lung cancer (SCLC) can be a highly aggressive form of lung cancer and can be difficult to treat. It is the rarest of the major lung cancer types and represents just 15% of all diagnoses. Unfortunately, few meaningful treatment advancements or improvements in survival rates have occurred [...]

FDA Approves First Targeted Therapy, Enhertu, for the Treatment of NSCLC With an Activating HER2 Mutation

August 15th, 2022|Hot Topics, News|

On August 11th, 2022, the Food and Drug Administration (FDA) approved Enhertu (fam- trastuzumab deruxtecan-nxki) for treatment of advanced non-small cell lung cancer (NSCLC) with an activating HER2 mutation for patients who have received one prior line of therapy. The FDA based their approval on the results of the [...]

New Survey Breaks the Silence on Women, Lung Cancer and Sexual Health

August 9th, 2022|Hot Topics, Monthly Measure, News, Newsletter Articles, Press Releases, Science and Research|

A groundbreaking new survey, conducted by a multi-disciplinary team in GO2 for Lung Cancer’s Lung Cancer Registry, found that sexual dysfunction is prevalent in women with lung cancer. The results were shared by study lead Dr. Narjust Florez (Duma) with top clinicians, researchers and scientists from across the world on [...]

GO2 for Lung Cancer Honors Dr. Rafael Rosell with the Bonnie J. Addario Lectureship Award

August 2nd, 2022|Hot Topics, News, Press Releases|

GO2 for Lung Cancer recognized Dr. Rafael Rosell at the 23rd International Lung Cancer Congress for his global contributions to oncology, particularly in the field of non-small-cell lung cancer (San Carlos, CA and Washington, DC) – GO2 for Lung Cancer has presented Dr. Rafael Rosell with the 2022 Bonnie [...]

Targeted Therapy Treatment Updates from ASCO 2022

June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding of how to treat non-small cell lung cancer (NSCLC) with [...]

New Treatments on the Horizon for Small Cell Lung Cancer

June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Author: Jennifer C. King, PhD, Chief Scientific Officer People diagnosed with small cell lung cancer (SCLC) have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, results from a few key studies were presented for the [...]

Immunotherapy Treatment Updates from ASCO 2022: Combinations, Resistance and More

June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Many patients with non-small cell lung cancer (NSCLC) rely on a class of treatments called immunotherapy to battle their cancer. The significant difference between immunotherapy and targeted therapy (the other main type of treatment that patients with NSCLC receive) is [...]

Coming Together for Equitable Cancer Care

June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program One of the priorities of GO2 for Lung Cancer, alongside many other ally organizations, is to ensure that people diagnosed with lung cancer receive optimal care regardless of their background, socioeconomic status, race or ethnicity. Collectively, we’re working to break [...]

Treatments Beyond Surgery: Early-stage Options from ASCO 2022

June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer (NSCLC) are generally broken down into two groups: those who can receive surgery to remove their tumor(s) and those [...]

A Caregiver’s Evolution: From Shock to Engaged Advocate

May 31st, 2022|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

By Kent Smith, lung cancer caregiver, advocate and GO2 for Lung Cancer Phone Buddy When my wife Debra was diagnosed with lung cancer in 2018, we were in shock. She had been having issues with her hip, which, after several weeks of physical therapy, didn’t resolve. An MRI revealed [...]

Four Takeaways from the 2022 Lung Cancer Voices Summit

May 31st, 2022|Advocacy in Action, Community Engagement, Hot Topics, Monthly Measure, Newsletter Articles|

Lung cancer advocates from across the country—and world—gathered virtually on May 16-17th at GO2 for Lung Cancer’s annual Lung Cancer Voices Summit. Participants learned about the latest research and treatment developments from experts in the field, received professional advocacy training and met with elected leaders to tell them lung [...]

Survivor Spotlight: Lindy A.

May 31st, 2022|Hot Topics, Monthly Measure, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Survivors, Women|

My name is Lindy Arman and I was diagnosed with small cell lung cancer (SCLC) in April 2020. I had recently had knee surgery which resulted in leg swelling that landed me in the emergency room. While there, they performed bloodwork which revealed extremely low sodium levels—which I now [...]

Statement on the passing of Norman Mineta GO2 for Lung Cancer Board Emeritus, Lung Cancer Survivor, former Transportation Secretary and Cabinet Member for Bill Clinton and George W. Bush

May 5th, 2022|Hot Topics, News|

Our hearts are heavy as we mourn the passing of Norm Mineta, an extraordinary man, public servant and lung cancer advocate. As an Asian-American he overcame hardships and prejudices early in life to go on to serve at the highest levels of government.  Beyond his long and respected career [...]

Small Cell Lung Cancer Transformation: What Is It and How Do We Treat It?

April 28th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people diagnosed with non-small cell lung cancer (NSCLC) with an EGFR [...]

Immune Checkpoint Inhibitor Resistance: What To Do Next?

April 28th, 2022|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer Immunotherapy, a type of treatment that helps the body’s own immune system fight cancer, is often discussed as a first line of treatment for people with metastatic non-small cell lung cancer (mNSCLC) without an actionable biomarker, [...]

New Screening Guidelines: How They Affect You and What You Need To Know

April 28th, 2022|Magnifying LeNS, News, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; Anita K. McGlothlin, Senior Director, Economics & Health Policy, GO2 for Lung Cancer; Angela Criswell, MA, CPS, Director, Quality Screening and Program Initiatives, GO2 for Lung Cancer Lung cancer screening using low dose computed tomography (LDCT) is [...]

Considering Caregivers: The Lung Cancer Registry’s Newest Initiative

April 28th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: John Wells, MBA, Senior Specialist, Lung Cancer Registry; Jamie L. Studts, PhD, Professor of Medical Oncology and Scientific Director of Behavioral Oncology, University of Colorado School of Medicine; GO2 for Lung Cancer Scientific Leadership Board Member; International Caregiver Survey Working Group; Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, [...]

Young People Get Lung Cancer Too. We Need to Know Why.

April 25th, 2022|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

“It took a total of about eight months, four or five doctors visits and multiple X-rays to eventually get that stage IV diagnosis.” -Stephen Huff, lung cancer survivor diagnosed at age 28 When you think about diseases impacting young people, lung cancer might not be at the top of [...]

Meet John: Behind the Scenes of the Lung Cancer Registry

April 25th, 2022|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

John Wells, MBA-HA is the senior specialist on GO2 for Lung Cancer’s Lung Cancer Registry team. We sat down with John to talk about his role with the Registry, his experience as a health care professional and his advice for people living with lung cancer and their loved ones. My [...]

Survivor Spotlight: Marianne G.

April 25th, 2022|Monthly Measure, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Stories of Hope, Survivors, Women|

My name is Marianne Gordon. In 2008, at 41 years old, I was rushed to the emergency room after passing out due to a collapsed lung. I had been seeing my doctor prior to this because my blood pressure kept mysteriously dropping which was attributed to some sort of [...]

Oncology Social Worker Brings Passion and Patients to the Lung Cancer Voices Summit

March 30th, 2022|Advocacy in Action, Hot Topics|

Kerri Susko, LISW-CP, OSW-C, MBCT Certified, was recruited to move to Prisma Health in Greenville, SC, when she joined the start-up team for the Center for Integrative Oncology and Survivorship. She provides individual psychotherapy to patients and family members. She’s also the Director of the Cancer Support Community at [...]

Walking Side by Side: A Call for Caregiver Support

March 28th, 2022|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

By GO2 for Lung Cancer with Jamie L. Studts, PhD, Professor of Medical Oncology and Scientific Director of Behavioral Oncology, University of Colorado School of Medicine; GO2 for Lung Cancer Scientific Leadership Board Member; International Caregiver Survey Working Group Caregivers for patients with lung cancer offer vital support [...]

Expanding Access to Lung Cancer Screening: Top 3 Things You Should Know

March 28th, 2022|Hot Topics, Monthly Measure, Newsletter Articles|

Authors: Anita K. McGlothlin, Senior Director, Economics & Health Policy, GO2 for Lung Cancer and Angela Criswell, MA, CPS, Director, Quality Screening and Program Initiatives, GO2 for Lung Cancer Lung cancer screening with a low-dose computed tomography (also known as low-dose CT or LDCT) scan is the only current, [...]

FDA Approves New Combination Treatment Before Surgery for Early-Stage NSCLC

March 7th, 2022|Hot Topics, News, Science and Research|

On March 4th, 2022, the Food and Drug Administration (FDA) approved Opdivo (nivolumab) for treatment before surgery in combination with platinum-based chemotherapy in patients with stage IB to IIIA non-small cell lung cancer (NSCLC). The approval was based on the results of the clinical trial CHECKMATE-816 which showed that [...]

The Lung Cancer Registry Launches New International Survey Focused on Experiences and Mental Health of Caregivers

March 1st, 2022|Hot Topics, News, Press Releases, Science and Research|

Through the first step of information collection, GO2 for Lung Cancer attempts to provide real tailored support programs to the caregivers of people around the world living with lung cancer SAN CARLOS, Calif. and WASHINGTON, D.C., March 1, 2022 – In an attempt to bolster support for caregivers in [...]

New and Improved Lung Cancer Registry

February 23rd, 2022|Hot Topics, Magnifying LeNS, News, Newsletter Articles, Science and Research|

First and Only Global Lung Cancer Registry Through its Lung Cancer Registry, GO2 for Lung Cancer securely gathers information from lung cancer patients across the globe - providing researchers with rich data from which to identify trends that can lead to new and better treatments for lung cancer patients. [...]

A Powerlifter Turned Oncology Nurse Practitioner and a Marketing Pro Who Wanted to Run Away with the Band

February 23rd, 2022|Hot Topics, Monthly Measure, News, Newsletter Articles|

Meet Joelle Fathi, DNP, and Lori Millner, two women poised to help GO2 for Lung Cancer and the lung cancer community as we expand our activities and work together to double survivorship rates by 2025. Meet Joelle Fathi, Powerlifter Turned Oncology Nurse Practitioner As GO2 for Lung Cancer's new [...]

New Medicare Lung Cancer Screening Guidelines a Huge Step Forward — More Lives to be Saved

February 14th, 2022|Hot Topics, News, Press Releases|

Providers Should Pursue Quality Assurance as Screening Proliferates New Centers for Medicare and Medicaid Services (CMS) recommendations to lower lung cancer screening (LCS) initial age and smoking history requirements can make these exams the most effective cancer screening tests in history. The American College of Radiology® (ACR®), the GO2 [...]

Fundraiser Spotlight: Luis E. Raez, MD, FACP, FCCP

February 3rd, 2022|Community Engagement, Fundraisers, Hot Topics, Spotlights|

Luis E. Raez, MD, FACP, FCCP Meet Luis E. Raez, MD, FACP, FCCP, Medical Director & Chief Scientific Officer; Memorial Cancer Institute, Memorial Health Care System; Clinical Professor of Medicine; Herbert Wertheim College of Medicine, Florida International University and GO2 for Lung Cancer Scientific Leadership Board member. [...]

Small Cell Lung Cancer Initiative 2021 Recap and Future Directions

January 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Authors: Amy Kampschroeder MA, OTR/L, CHES, Manager, Patient Outreach and Special Initiatives and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program In 2021, one of GO2 for Lung Cancer’s priorities continued to be bringing lung cancer education and empowerment to patients to help ensure equitable healthcare. One of the tools GO2 for Lung Cancer used and [...]

Navigating Biomarker Testing Issues

January 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Senior Manager of Clinical Research Due to the increasing number of approved targeted therapies for the treatment of lung cancer, clinical guidelines recommend that every patient receive comprehensive biomarker testing. Despite the importance of comprehensive biomarker testing, some people with lung cancer can face barriers [...]

FDA Approvals: New Treatment Landscape in 2022

January 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for patients. Additionally, [...]

Identification of Chemoradiation Response Mediators in Non‐Small Cell Lung Cancer via Circulating Tumor DNA Analysis

January 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Everett Moding, MD, PhD, Assistant Professor Department of Radiation Oncology, Stanford University School of Medicine A combination of chemotherapy and radiation therapy (chemoradiation therapy) is the backbone of treatment for non-small cell lung cancer (NSCLC) that has spread to the lymph nodes in patients who are not candidates [...]

GO2 for Lung Cancer Hires Lori Millner as Chief Marketing Officer

January 27th, 2022|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON, January 27, 2022 — GO2 for Lung Cancer (GO2 for Lung Cancer) has hired Lori Millner to serve as Chief Marketing Officer (CMO). In this position, Ms. Millner will oversee global and national marketing efforts to advance GO2 for Lung Cancer’s mission of transforming survivorship by saving, extending, and improving [...]

REGISTRATION OPEN: 2022 Virtual Lung Cancer Voices Summit

January 25th, 2022|Advocacy in Action, Community Engagement, Hot Topics, News|

Tell Congress It's Personal Registration is now open for the 2022 Virtual Lung Cancer Voices Summit, May 16-17. Don’t miss this opportunity to raise your voice to increase lung cancer research funding! Join advocates from across the country virtually for this inspirational two-day event to [...]

GO2 for Lung Cancer Launches Improved and Expanded Global Lung Cancer Registry

January 13th, 2022|Hot Topics, News, Press Releases, Science and Research|

Registry provides wealth of data to help lung cancer researchers “connect the dots” and empowers patients around the world to be part of uncovering solutions SAN CARLOS, Calif. and WASHINGTON, January 13, 2022 – To further advance lung cancer research by uncovering hidden connections between people with lung cancer [...]

Prioritizing You in 2022

January 12th, 2022|Hot Topics|

The past year was a challenge for so many, especially those impacted by lung cancer. Now more than ever, it’s important to prioritize YOU and your health and well-being. Going into 2022, here are four worthy commitments to consider. FIND SUPPORT Support in your lung cancer journey is beneficial [...]

GO2 for Lung Cancer and Key Stakeholders Call on Medicare to Expand Lung Cancer Screening Coverage

December 21st, 2021|Advocacy in Action, Hot Topics|

On March 9, 2021, GO2 for Lung Cancer, American College of Radiology (ACR), and the Society of Thoracic Surgeons (STS) urged the Centers for Medicare and Medicaid Services (CMS) to revise their Medicare coverage policy to reflect the new U.S. Preventive Services Task Force (USPSTF) eligibility thresholds and remove barriers [...]

The Football Bet: A College Fandom Rivalry Leads to Funding for Lung Cancer

December 17th, 2021|Hot Topics, Monthly Measure, Newsletter Articles|

It didn't take long for the trash-talking to start. As soon as Jamie Studts logged onto the Zoom call, Nancy Alvey needed a drink of water—from her University of Wisconsin (UW) mug. Studts, of course, had donned his University of Iowa (UI) fleece for the occasion. Meet Nancy Alvey: [...]

Creative Events in 2021: From Scavenger Hunt to Pop-up Drive-in

December 17th, 2021|Community Engagement, Hot Topics, Monthly Measure, Newsletter Articles|

Creativity might not be the official word of 2021, but the lung cancer community once again showed off its creativity in raising awareness and funds throughout the year. You didn’t have to golf across six states or hike to Mount Everest to participate, though there were of course some [...]

How to Live with Small Cell Lung Cancer: Matt’s Story

December 17th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Stories of Hope, Survivors, Veterans|

My name is Matt Peterson and I am a Vietnam veteran, father, and lung cancer survivor. After a single nodule was found in my lung in 2019, I was diagnosed with small cell lung cancer (SCLC). I was also diagnosed with diabetes. I’ve been through chemotherapy and immunotherapy, but [...]

Finding Hope in a Small Cell Lung Cancer Diagnosis

December 17th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Small Cell Lung Cancer, Stories of Hope|

When you hear the doctor say the words “small cell lung cancer,” life suddenly changes. You may feel overwhelmed and grieved, lost or angry, or you may feel nothing at all. It is okay to move through all kinds of emotions when you are processing a cancer diagnosis. The [...]

FDA Approvals: New Treatment Landscape in 2021

December 17th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for patients. Additionally, new immunotherapy options were approved, giving more variety [...]

GO2 for Lung Cancer’s 2021 Centers of Excellence Summit: The Power of Together

December 16th, 2021|Hot Topics|

Together, we build local excellence to confront lung cancer. GO2 for Lung Cancer’s Center of Excellence Program fosters and promotes the highest quality screening and treatment standards in lung cancer across a national network of local community hospitals. Through COEs, GO2 for Lung Cancer builds the confidence providers and [...]

Erika Hlavacek is Living Her Best Life

December 9th, 2021|Stories of Hope|

In September 2017, Erika Hlavacek was a commercial airline pilot living in the Chicago suburbs with her husband and two children when a cough and progressively worse back pain landed her in the hospital. She was diagnosed with stage 4 lung cancer. Comprehensive biomarker testing soon identified an ALK+ [...]

Improving Access to Comprehensive Biomarker Testing

December 9th, 2021|Advocacy in Action, Hot Topics|

National advocacy organizations, including GO2 for Lung Cancer, have been advocating for legislative policies to increase and improve access to biomarker testing. Those efforts are increasing, especially at the state level, as legislatures take up biomarker testing bills. Educating lawmakers is critical, as patients face enormous challenges around misdiagnoses [...]

GO2 for Lung Cancer Hires Joelle Fathi, DNP as Chief Healthcare Delivery Officer

December 2nd, 2021|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON, December 2, 2021 — GO2 for Lung Cancer (GO2 Foundation) has hired Joelle Fathi, DNP to serve as Chief Healthcare Delivery Officer. In this position Fathi will lead GO2  Foundation’s Excellence in Screening and Care department, which includes the GO2 Foundation Centers of Excellence, a network consisting of more than 850 [...]

Senate Passes Resolution Recognizing November as Lung Cancer Awareness Month

December 1st, 2021|Advocacy in Action, Hot Topics, News|

On November 30, Senators Marco Rubio (R-FL) and Tina Smith (D-MN) introduced and passed a Senate resolution recognizing November as Lung Cancer Awareness Month. The resolution helps elevate national attention to the disease and encourage more early detection and treatment research to improve outcomes for the millions at risk or [...]

Survivor Spotlight: A Black Woman’s Experience with Lung Cancer

November 16th, 2021|Hot Topics, Monthly Measure, Spotlights, Survivors, Women|

Hi, I'm Anne Charity Hudley, Ph.D., the North Hall Endowed Chair in the Linguistics of African America and the former Director of Undergraduate Research for the Office of Undergraduate Education at the University of California, Santa Barbara. I study the relationship between language variation and educational practices. I'm also [...]

GO2 for Lung Cancer Honors Champions of the Lung Cancer Community At the Simply the Best XVI Gala

November 15th, 2021|Community Engagement, Hot Topics, News, Press Releases|

Patients, researchers, physicians, and caregivers honored at annual event SAN CARLOS, Calif. and WASHINGTON, Nov. 15, 2021 /PRNewswire/ -- GO2 for Lung Cancer (GO2 for Lung Cancer) honored leaders in lung cancer research and treatment, as well as dedicated lung cancer caregivers at its Simply the Best XVI Gala held November 13 in San Mateo, CA. [...]

Treatments and Other Advances in Early-Stage Non-Small Cell Lung Cancer

October 28th, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Rashmi Acharya, MS, Science and Research Specialist, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) had multiple researchers presenting their findings on broad areas of research in early-stage lung cancer. These presentations bring highly encouraging news to the lung cancer community—an interest in understanding [...]

Moving the Needle in Small Cell Lung Cancer

October 28th, 2021|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Author: Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer The World Conference on Lung Cancer features research on all types of thoracic cancers—and small cell lung cancer is no exception. There were many talks on new research advances in small cell lung cancer (SCLC). While none [...]

GO2 In Action: Our Involvement in the 2021 World Conference on Lung Cancer

October 28th, 2021|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer This month, the GO2 for Lung Cancer team virtually attended IASLC’s 2021 World Conference on Lung Cancer. Our science and research team provided strong representation for the organization and the lung cancer community through a combination [...]

A New Look at Targeted Therapies for 2021 and Beyond

October 28th, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer and Jacinta R. Wiens, PhD, Director of Lung Cancer Registry, GO2 for Lung Cancer The World Conference on Lung Cancer (WCLC) highlighted many up-and-coming treatments for patients with different mutations, while also shedding light on proven [...]

A Look at Immunotherapies from the World Conference on Lung Cancer

October 28th, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Senior Manager of Clinical Research, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) saw several research presentations that helped increase our understanding of immunotherapy as a treatment for people with lung cancer and how we might better be able to use [...]

Global Lung Cancer Awareness Month Coalition Launches to Transform Survival

October 28th, 2021|Hot Topics, News, Press Releases|

Coalition seeks to increase awareness and support for the disease by acting locally, impacting globally. SAN CARLOS, Calif. and WASHINGTON DC, October 28, 2021 – The Global LCAM Coalition (LCAM Coalition), stewarded by  GO2 for Lung Cancer (GO2 for Lung Cancer), announced its launch, just in time for Lung [...]

FDA Approves Tecentriq for Adjuvant Treatment of Non-Small Cell Lung Cancer

October 15th, 2021|Hot Topics, News, Science and Research|

On October 15th, 2021, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for treatment following surgery and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression ≥ 1% as determined by a FDA-approved test. The approval was based on the results of the clinical trial [...]

Ways to Shine A Light on Lung Cancer

October 7th, 2021|Community Engagement, Hot Topics, Monthly Measure, Newsletter Articles|

Shine a Light on Lung Cancer is the largest coordinated lung cancer awareness program in the United States. Hosted by healthcare facilities during Lung Cancer Awareness Month (November), Shine a Light on Lung Cancer educates, connects, and celebrates our community while raising awareness about the disease. In light of the [...]

The 2021 World Conference on Lung Cancer

October 7th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Don’t miss our deep dive on topics presented at IASLC's 2021 World Conference on Lung Cancer, including presentations from our very own GO2 for Lung Cancer Science and Research Team. Subscribe to our Magnifying LeNS newsletter and look out for our upcoming special issue on WCLC. By Rashmi [...]

A Mother’s Love

September 23rd, 2021|Community Engagement, Hot Topics|

Written by Nicole Famularo My mom’s cancer story started in July 2013, although, we came to find out much later that the tumor had probably started to develop years prior to her diagnosis.  My parents, my four siblings, and I went to Sandbridge in Virginia Beach, it was our [...]

FDA Approves Exkivity for Advanced NSCLC with EGFR Exon 20 Insertion Mutation

September 16th, 2021|Hot Topics, News, Science and Research|

On September 15th, 2021, the Food and Drug Administration (FDA) approved Exkivity (mobocertinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of a clinical trial which showed that patients receiving Exkivity [...]

Aurora BayCare Medical Center Launches Program to Bridge Gap from Treatment to Survivorship

September 9th, 2021|Hot Topics, Monthly Measure, Newsletter Articles|

There’s this quiet that often happens when a cancer patient completes treatment. You go from having your life overwhelmed by doctors, nurses, technicians, and treatments to having nowhere you need to be. Depending on the facility (and the patient), the health care team might ring a bell or otherwise [...]

Treating KRAS G12C Mutated Lung Cancer: A Personal Look

September 9th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

Stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated in recent years by the genetic mutation, or biomarker. Patients received either chemotherapy, immunotherapy, a combination of the two, or a personalized targeted therapy depending on the biomarkers in their cancer. During this period, only a few [...]

Antibody Response to COVID-19 Vaccination in People with Lung Cancer

September 8th, 2021|Hot Topics, News, Science and Research|

At the World Conference on Lung Cancer, Dr. Jorge Gomez, MD from Icahn School of Medicine at Mount Sinai, New York presented new data on how people with lung cancer respond to vaccination against the SARS-CoV-2 virus that causes COVID-19. The presentation was on behalf of a research consortium [...]

Exciting Breakthrough in Lung Cancer Precision Medicine

September 7th, 2021|Hot Topics, Science and Research|

For several years stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated by the genetic mutation, called biomarkers, of the patient. A patient’s treatment was seen as either chemotherapy, immunotherapy (or some sort of combination of the two), or a personalized targeted therapy. In the early [...]

National Non-Profit Day

August 19th, 2021|Hot Topics|

This week marked National Non-Profit Day on August 17 to recognize the positive impact of non-profits in the US and communities around the world. People are encouraged to observe this day by learning more about the benefits of supporting a non-profit that often do so much more than fulfill [...]

GO2 for Lung Cancer Expands Scientific Leadership Board in Effort to Double Five-Year Survival Rate by 2025

August 5th, 2021|Hot Topics, News, Press Releases, Science and Research|

SAN CARLOS, Calif. and WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- With the goal of doubling the five-year survival rate of lung cancer patients from 20 percent to 40 percent by 2025, today the GO2 for Lung Cancer (GO2 for Lung Cancer) announced it is expanding its Scientific Leadership Board (SLB). GO2 for Lung Cancer's SLB [...]

Turning the Sound Up on Comprehensive Biomarker Testing

July 29th, 2021|Hot Topics, Science and Research|

We're turning the sound up on comprehensive biomarker testing. Every person’s cancer is different. Between all of the lung cancer treatment options available, how can you and your treatment team identify the best path for your individual case? Enter: comprehensive biomarker testing. Comprehensive biomarker testing looks for biological changes [...]

Ensuring Health Equity in Cancer Care

July 21st, 2021|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer “Equity: Every Patient. Every Day. Everywhere.” That was the theme for this year’s American Society for Clinical Oncology (ASCO) Annual Meeting. And, indeed, the theme of health equity ran through the meetings tracks and presentations right from the [...]

New Research Unlocks Promise for Treating Small Cell Lung Cancer

July 21st, 2021|Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung Cancer Unlocking the Biology of SCLC Patients with small cell lung cancer (SCLC) receive one-size-fits-all treatment because of limited knowledge about the biology of the disease. There are currently no actionable biomarkers for SCLC; thus immunotherapy and chemotherapy [...]

Adding New Drugs to Treatment for Early Stage Lung Cancer

July 21st, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers are exploring whether adding therapies currently used to treat advanced [...]

New Targeted Therapies in the Biomarker Space

July 21st, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

By Andrew Ciupek,  PhD, Senior Manager, Clinical Research, GO2 for Lung Cancer and Daniel A. Saez, MSc, Navigator, Treatment & Trials, GO2 for Lung CancerNew Hope for Patients with KRASUntil recently, the KRAS mutation was considered un-targetable in most types of cancer, including lung cancer. May 2021 marked the approval [...]

Revisiting EGFR

July 21st, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso remains an important and effective standard of care option for [...]

Immunotherapy Update

July 21st, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung CancerChemotherapy has been the standard treatment option for Non-Small Cell Lung Cancer (NSCLC) without actionable biomarkers. Recently, immunotherapy treatments have been added into the treatment mix. Several studies presented at the American Society of Clinical Oncology’s Annual Meeting offer [...]

Endurance Golf, Speed Golf, and a Passion for Ending Lung Cancer

July 8th, 2021|Community Engagement, Hot Topics, Monthly Measure, Newsletter Articles|

Curt Groebner is passionate about golf—and fighting cancer. So passionate that he convinced 3 friends to play golf with him, once a year, for 24 hours straight. For 10 years. In the process he raised over $68,000, much of it for GO2 for Lung Cancer. “In our fourth year, [...]

First, the Phone Buddy Program gave her a lifeline.

July 8th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Stories of Hope|

Wendy (left) with her Phone Buddy, Cecily (right) Then the Phone Buddies became friends. Wendy Williams and Cecily Hatchitt met through GO2 for Lung Cancer’s Phone Buddy Program. Then they became something more: friends. Meet Wendy Williams, a Kennesaw, GA, resident who reached out to GO2 for [...]

Research into Acquired Drug Resistance in Patients with ALK+ NSCLC

June 10th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

Amanda Nerstad, SPACEWALK participant, with family By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer One of the biggest concerns within the mutation positive non-small cell lung cancer (NSCLC) community is the concept of acquired resistance to targeted therapies. Acquired resistance is when [...]

This Physician is on a Mission to Screen Every High-Risk Kentuckian

June 10th, 2021|Community Engagement, Hot Topics, Monthly Measure, Newsletter Articles|

Kentucky has a lung cancer problem. Michael Gieske, MD, is on a mission to raise awareness about the disease and detect, treat, and save as many people as possible. A primary care physician, Gieske is the director of lung cancer screening at St. Elizabeth's HealthCare. The Kentucky native [...]

Highlights from ASCO 2021

June 10th, 2021|Hot Topics, Science and Research|

By Rashmi Acharya, MS; Andrew Ciupek, PhD; Jennifer C. King, PhD; and Daniel Saez, MSc  The annual meeting held by the American Society of Clinical Oncology (ASCO) is the stage for presenting many of the most impactful advancements in cancer research – including in lung cancer.  Health equity was the major theme of the 2021 meeting, held June 4-8, 2021, and multiple studies showed that there are many disparities in lung cancer care [...]

GO2 for Lung Cancer Expands Early Detection Efforts to Include Incidental Pulmonary Nodules (IPN) to Save More Lives

June 10th, 2021|Hot Topics, News, Press Releases|

GO2 for Lung Cancer to launch a webinar series and toolkit on building IPN management programs SAN CARLOS, Calif. and WASHINGTON, D.C., June 10, 2021 – To help diagnose early-stage lung cancer when it is more treatable and even curable, GO2 for Lung Cancer (GO2 for Lung Cancer) is [...]

Legislation Introduced for Lung Cancer Screening and Early Detection

June 9th, 2021|Advocacy in Action, Hot Topics, News, Press Releases|

We are proud to endorse and provide strong support for Katherine’s Lung Cancer Early Detection and Survival Act of 2021, introduced by our House Congressional Lung Cancer Caucus Chair Representative Brendan Boyle (D-2-PA) and co-champion Senator Tina Smith (D-MN). Recognizing that too many lives are lost to lung cancer [...]

First Targeted Therapy Approval for Non-Small Cell Lung Cancer with KRAS Mutation

May 28th, 2021|Hot Topics, News, Science and Research|

On May 28, 2021 the United States Food and Drug Administration (FDA) approved Lumakras (sotorasib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having the G12C change in KRAS. The FDA based their approval on the results of the clinical trial CODEBREAK 100 which [...]

FDA Approves Rybrevant as First Targeted Treatment for Patients with NSCLC with EGFR Exon 20 Insertion Mutations

May 24th, 2021|Hot Topics, News, Science and Research|

On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of the clinical trial CHRYSALIS which showed that patients receiving Rybrevant [...]

GO2 for Lung Cancer’s Focus on Women and Lung Cancer

May 11th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research|

May is Women’s Health Month, and GO2 for Lung Cancer has partnered with the Addario Lung Cancer Medical Institute to investigate how and why some young women’s rates of lung cancer are increasing, despite never having smoked. Watch the video below from GO2 for Lung Cancer’s Dr. Andrew Ciupek to learn more.  [...]

GO2 for Lung Cancer Seeks to Better Understand Needs of People with Small Cell Lung Cancer

May 11th, 2021|Hot Topics, News, Press Releases, Science and Research, Small Cell Lung Cancer|

Innovative effort aims to improve outcomes for historically underserved lung cancer patient community. SAN CARLOS, Calif. and WASHINGTON, D.C., May 11, 2021 – GO2 for Lung Cancer (GO2 for Lung Cancer) has launched a landmark initiative to identify the needs of the Small Cell Lung Cancer (SCLC) community. SCLC [...]

The Impact of Lung Cancer Across Generations: One Family’s Story

May 7th, 2021|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles|

Usha Jain (left) and daughter, Amita Jain (right) Lung cancer doesn’t just impact one person—it affects all those who love them. Perhaps no family understands this better than the Jain-Patkar family. Meet Usha Jain, a retired professor in the Department of South and Southeast Asian [...]

GO2 for Lung Cancer Statement on Proposed FDA Actions on Menthol Cigarettes

April 29th, 2021|Advocacy in Action, Hot Topics, News|

Today, the U.S. Food and Drug Administration (FDA) announced it is working toward issuing proposed rulemaking to ban menthol as a characterizing flavor in cigarettes and ban all characterizing flavors (including menthol) in cigars to reduce disease and death from use of combusted tobacco products in the United States. [...]

A Call for Major Commercial Payers to Revise Screening Coverage

April 15th, 2021|Advocacy in Action, Hot Topics, News|

We recently requested that payers (healthcare insurance companies) expeditiously update their lung cancer screening (LCS) coverage policies in accordance with the recently updated United States Preventive Services (USPSTF) guidelines. In concert with other key stakeholders, letters were sent to the top five national private insurance companies—Aetna, Anthem, Cigna, Health Care Services Corporation, [...]

A Primer on Small Cell Lung Cancer and the Role of Clinical Trials in Treatment

April 13th, 2021|Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung Cancer 1. What is Small Cell Lung Cancer? Small cell lung cancer (SCLC) is a type of lung cancer named for the very small, oval shaped cancer cells seen under a microscope. It is a rapidly growing type [...]

Treatment Insights for KRAS Mutated Non-Small Cell Lung Cancer

April 13th, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer Rebecca (KRAS driven stage 4 NSCLC patient) and Wayne Yeung (caregiver) Since the original publication of this article, the United States Food and Drug Administration (FDA) approved Lumakras (sotorasib) for the first [...]

What is Small Cell Lung Cancer?

April 8th, 2021|Hot Topics, Monthly Measure, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

By Daniel A. Saez, M.Sc., Treatment and Trials Navigator, GO2 for Lung Cancer Patients diagnosed with Small Cell Lung Cancer (SCLC) have new hope because of recent advances in early detection and treatment. To amplify this positive message, we are working with industry partners to empower patients diagnosed with [...]

Five Communities Spring Into Action for GO2 for Lung Cancer

April 8th, 2021|Community Engagement, Monthly Measure, Newsletter Articles|

Thank you to everyone who joined us for our first-ever Step into Spring Virtual Step Challenge! You blew our goal out of the water, logging over 10 Million Steps for lung cancer and raising over $91,000 for our programs dedicated to doubling lung cancer survival. Congratulations! You came out [...]

Advocacy for Lung Cancer is Personal

April 7th, 2021|Advocacy in Action, Hot Topics, Monthly Measure, Newsletter Articles|

What an impact our community can make! On March 23-25, 2021, we brought together survivors, patients, caregivers, family & friends, healthcare professionals to listen, learn, share, and tell their members of Congress about the needs of the lung cancer community and demand action. Look at the numbers: 160 [...]

Physician and Patient Groups Call On CMS to Update Medicare Lung Cancer Screening Coverage

March 18th, 2021|Advocacy in Action, Hot Topics, Press Releases|

New Medicare Coverage Should Reflect USPSTF Eligibility Thresholds and Reduce Barriers to Care Washington (March 18, 2021) -- Medicare lung cancer screening coverage should be updated to reflect new  U.S. Preventive Services Task Force (USPSTF) eligibility thresholds and remove barriers that keep at-risk populations from accessing these lifesaving exams. [...]

Take Action! Email, Tweet, Tell Congress to Support Lung Cancer Research

March 17th, 2021|Advocacy in Action, News|

At the 2021 Lung Cancer Voices Summit, advocates across the lung cancer community will come together to learn, network, and raise awareness about lung cancer and the need to focus funding for research and new treatment options. This year’s theme is Tell Congress It’s Personal. Lung cancer is personal—to [...]

Life-Saving Screening Expands to Reach More Americans

March 9th, 2021|Advocacy in Action, Hot Topics, News|

Today, the United States Preventive Services Task Force (USPSTF) published its final recommendation for low dose CT lung cancer screening, which expands screening recommendations by lowering the age minimum to 50 years and lowering the smoking history to 20-pack years. We commend the USPSTF for bringing life-saving screening to more [...]

At Dignity Health, AZ, Finding Inspiration as a Team

March 9th, 2021|Community Engagement, Hot Topics|

Norton Thoracic Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix, AZ is taking teamwork on behalf of the lung cancer community to an entirely new level.  Dignity Health’s Norton Thoracic Institute has a multidisciplinary program dedicated to catching and diagnosing early lung cancer via [...]

FDA Updates Approval for Lobrena to First Line Treatment for Advanced NSCLC Patients with Changes in ALK

March 4th, 2021|Hot Topics, News, Science and Research|

On March 3rd, 2021, the Food and Drug Administration (FDA) approved Lobrena (lorlatinib) for the first line treatment of non-small cell lung cancer (NSCLC) which has spread outside of the lungs that has a change in ALK identified by an FDA approved test. The FDA based their approval on [...]

GO2 for Lung Cancer Leads Study to Improve Participation of Black Communities in Lung Cancer Clinical Trials

March 4th, 2021|Hot Topics, News, Press Releases, Science and Research|

SAN CARLOS, Calif. and WASHINGTON – GO2 for Lung Cancer (GO2 for Lung Cancer) announced its leadership in the launch of an important multi-institutional study to determine how to improve the participation of Black communities in lung cancer clinical trials. While participation in clinical trials by all cancer patients in the [...]

FDA approves new immunotherapy, Libtayo, for patients with metastatic NSCLC and high PD-L1

February 23rd, 2021|Hot Topics, News, Science and Research|

On February 22nd, 2021, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for the treatment of advanced non-small cell lung cancer (NSCLC) with no changes in EGFR, ALK, or ROS1 but with high PD-L1. The FDA based their approval on the results of a clinical trial which found [...]

New Study Seeks Origins of Young Lung Cancer

February 23rd, 2021|Hot Topics, News, Press Releases|

Addario Lung Cancer Medical Institute and GO2 for Lung Cancer to learn about environmental, lifestyle, and demographic risks of developing lung cancer under the age of 40 San Carlos, CA/Washington DC – Continuing their collaboration to transform lung cancer survival and to accelerate novel research advancements for people with [...]

GO2 for Lung Cancer Advocates for COVID-19 Vaccine Prioritization

February 17th, 2021|Advocacy in Action, Hot Topics|

Today, GO2 for Lung Cancer joined a broad spectrum of organizations representing laboratory, translational, and clinical researchers; other health care professionals; patients with cancer; and patient advocates in sending a letter to the Biden administration and other public health officials that highlights the importance of prioritizing patients with active [...]

New Therapy for Small Cell Lung Cancer Patients: FDA Approval of COSELA (trilaciclib)

February 16th, 2021|Hot Topics, News, Science and Research|

On February 12th, 2021, the Food and Drug Administration (FDA) approved Cosela (trilaciclib) for patients with extensive stage small cell lung cancer (ES-SCLC) (cancer which has spread outside of the lung) to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy. The [...]

FDA Approves Tepmetko (tepotinib) for NSCLC with MET Exon 14 Skipping Mutations

February 4th, 2021|Hot Topics, News, Science and Research|

On February 3rd, 2021, the Food and Drug Administration (FDA) approved Tepmetko (tepotinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET called exon 14 skipping. The FDA based their approval on the results of the clinical trial VISION which showed that patients had a [...]

Vaccine Prioritization

January 27th, 2021|News|

Because of the dual impact on our respiratory system, we’ve coined the term Lung Cancer + COVID-19 = Twice the Problem in an earlier blog post. Another strong step has been taken in our comprehensive strategy to elevate the needs of our community by reinforcing that those with lung cancer [...]

Update for Week of Jan 25 to the Joint Statement on COVID-19 From Lung Cancer Advocacy Groups

January 25th, 2021|Hot Topics, News, Science and Research|

As of January 22, we stand at 24.8 million COVID-19 cases in the US, with 412,936 deaths. The CDC reports that 15.1 million Americans have received at least one dose of vaccine, with 2.4 million people being fully vaccinated. President Biden and his administration have made addressing the COVID-19 pandemic [...]

1 + 1 = Twice the Problem

January 15th, 2021|Hot Topics, News|

We are now several weeks into the new year. The good news is that we now have COVID-19 vaccines approved. The bad news is that the vaccines are not getting to people quick enough, especially to those with lung cancer who are at an increased risk because of co-morbidities.Both lung [...]

Learning About Everyone: The Importance of Advancing Inclusive Research

January 14th, 2021|Magnifying LeNS, Science and Research|

By Jennifer C. King, Ph.D., Chief Scientific Officer, GO2 for Lung Cancer Are scientists learning enough about how people just like you respond to new treatments? You may be surprised. Clinical trial participation rates among people with cancer in the United States are low, with only about 8% of those [...]

Lung Cancer Registry: Partnering with Patients and Caregivers to Drive Research Forward

January 14th, 2021|Magnifying LeNS, Science and Research|

By Jacinta R. Wiens, Ph.D., M.S., Director, Lung Cancer Registry, GO2 for Lung Cancer The Lung Cancer Registry (LCR), created by the GO2 for Lung Cancer, is a global online database that was launched in 2016. The LCR was designed so that patients could contribute their individual experiences with lung [...]

How Biomarker Testing Affects Patients

January 14th, 2021|Magnifying LeNS, Science and Research|

By Daniel A. Saez, M.Sc., Treatment and Trials Navigator, GO2 for Lung Cancer In today’s lung cancer care landscape, biomarker testing has become a crucial part of the treatment decision for many oncologists. Targeted therapies can be more effective than chemotherapy for patients with driver mutations123 including approved medications [...]

Trends in Treatment of EGFR+ NSCLC after Progression Following Tagrisso Treatment

January 14th, 2021|Magnifying LeNS, Science and Research|

By Andrew Ciupek, Ph.D., Manager, Clinical Research, GO2 for Lung Cancer Approximately 30% of Non-Small Cell Lung Cancers (NSCLC) have an EGFR mutation. For these patients EGFR targeted therapy has greatly increased survival. Tagrisso (osimertinib) has become the drug of choice for EGFR+ (positive) NSCLC treatment after the FLAURA [...]

Another Step for Early Detection

December 22nd, 2020|Advocacy in Action, Hot Topics, News|

We are proud to support S. 5051, the Multi-Cancer Early Detection Screening Coverage Act and applaud the leadership U.S. Senators Mike Crapo (R-Idaho), Michael Bennet (D-Colorado), Tim Scott (R-South Carolina) and Ben Cardin (D-Maryland).  This step follows an early December introduction of H.R. 8845 in the House of Representatives. [...]

First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer

December 21st, 2020|Hot Topics, News, Science and Research|

On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for the adjuvant treatment of stage IB-IIIA non-small cell lung cancer (NSCLC) that has been surgically removed, when the cancer has a change in EGFR. The FDA based their approval on the results of the clinical [...]

Update for Week of Dec 14 to the Joint Statement on COVID-19 From Lung Cancer Advocacy Groups

December 14th, 2020|Hot Topics, News, Science and Research|

The first case of COVID-19 in the USA was reported on 1/20/2020—over 10 months ago. Since then, the country has reported 15,718,811cases and 294,535 deaths as of December 12 (per the Centers Disease Control and Prevention). With 80% of US counties reporting more travel than last year over Thanksgiving weekend [...]

Removing Barriers to Screening: A Policy Update

December 8th, 2020|Advocacy in Action, Hot Topics, News|

We are proud to support H.R. 8845, the Multi-Cancer Early Detection Screening Coverage Act and applaud the leadership of U.S. Reps. Terri Sewell (AL-07), Jodey Arrington (TX-19), Raul Ruiz (CA-36).  GO2 for Lung Cancer’s overarching mission is to transform survivorship for those impacted by the disease.  A cornerstone to [...]

Why Give?

December 3rd, 2020|Hot Topics|

Giving Tuesday may have passed but with the season of giving upon us, now is the perfect time to join the fight against lung cancer. Over 228,820 people were diagnosed with lung cancer this year, making it the leading cause of cancer death for both men and women across [...]

Update for Week of Nov 23 to the Joint Statement on COVID-19 From Lung Cancer Advocacy Groups

November 23rd, 2020|Hot Topics, News|

We are at a critical moment in the ongoing COVID-19 pandemic. New cases are rapidly escalating throughout the country, and we are positioned to see explosive growth as people travel and gather to celebrate the Thanksgiving holiday with loved ones. While our understanding of how to treat COVID-19 has [...]

Delivering Excellence in Care Closer to Home

November 10th, 2020|Hot Topics, News|

As we enter Lung Cancer Awareness Month, our mantra of “Lung Cancer: It’s Personal” could not have been on display better than during our recent 2020 Centers of Excellence (COE) Summit. This event brought together more than 300 healthcare providers, industry partners and patients to discuss successes, innovations and [...]

Bench to Bedside and Back Again

November 9th, 2020|Hot Topics, Monthly Measure, Science and Research|

Today’s blog presents Christine Lovly, MD, PhD, Associate Professor of Medicine, Ingram Associate Professor of Cancer Research, and Co-leader of the Translational Research and Interventional Oncology Research Program at Vanderbilt University Medical Center. Dr. Lovly was recently named Chair of our Scientific Leadership Board. She is a highly recognized oncologist and [...]

3 Facts About Clinical Trials Every Patient Should Know

November 9th, 2020|Hot Topics, Monthly Measure, Science and Research|

The World Health Organization defines a clinical trial as “a type of research that studies new tests and treatments and evaluates their effects on human health outcomes.” Put simply, it’s a research study involving people, often used to evaluate the safety and effectiveness of new drugs and other therapies. [...]

GO2 for Lung Cancer “Simply the Best” XV Virtual Gala Honors Those Working on the Front Lines to Fight Lung Cancer

October 22nd, 2020|Community Engagement, Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON, Oct. 22, 2020 /PRNewswire/ -- GO2 for Lung Cancer announced it will celebrate Genentech with the "Simply the Best Award" at its XV Virtual Annual Simply the Best Gala on November 14, 2020 at 6:30 pm PT. Genentech will be honored for its continued dedication to research and development of new lung cancer treatments. [...]

Christine M. Lovly, MD, PhD, to Chair Scientific Leadership Board

October 21st, 2020|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- GO2 for Lung Cancer is pleased to announce that Christine Lovly, MD, PhD, has been named as the incoming chair of GO2 Foundation's Scientific Leadership Board (SLB). Dr. Lovly, an associate professor of Medicine, Ingram Associate Professor of Cancer Research, and co-leader of the Translational [...]

The Voice of Hope

October 15th, 2020|Hot Topics, News|

By: Laurie Fenton Ambrose, Co-Founder, President and CEO, GO2 for Lung Cancer Our Co-Founder and Board Chair Bonnie J. Addario is the recipient of the 2020 Lifetime Achievement Award from CURE Media Group. The award is part of the inaugural The 2020 Lung Cancer Heroes™ virtual celebration being held [...]

How Screening Centers Are Bringing Patients Back

October 6th, 2020|Monthly Measure|

Catching Lung Cancer Early Remains Critical Tool in Fighting the Disease When the Coronavirus shutdowns hit, a lot of primary and preventive care shut down with the pandemic. Slowly, as clinicians switched to telehealth appointments and facilities set up protocols to protect non-COVID-19 patients, patients started returning for treatment [...]

Practicing Medicine for the Patient

October 6th, 2020|Hot Topics, Monthly Measure, Science and Research|

Narjust Duma, MD, Principle Investigator of the SHAWL Study Today’s blog presents Narjust Duma, MD, Assistant Professor, Division of Hematology/Oncology, Medical Oncology, and Palliative Care, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. Dr. Duma (pictured left) is [...]

The Complete Story—GO2 for Lung Cancer and Biomarker Testing

October 6th, 2020|Hot Topics, Monthly Measure, Science and Research|

Comprehensive biomarker testing identifies what is unique about a lung cancer patient’s cancer, ensuring they receive appropriate treatment. Increasing the use of comprehensive biomarker testing is one of GO2 for Lung Cancer’s key goals. To reach it, we’re using a multipronged approach that includes patient education, assessing data on [...]

Lung Cancer Awareness in the Time of COVID-19

October 2nd, 2020|Hot Topics|

This is an unusual year for us all, but healthcare facilities are still focused on lung cancer education and awareness. To help them in this effort, we offer our Shine a Light on Lung Cancer program that provides hospitals with guidance and supportive educational materials for use during Lung [...]

Angela Criswell Wins the the 2020 Timothy W. Mullett, MD, Lung Cancer Prevention Award

October 1st, 2020|Hot Topics, News|

Angela Criswell, MA, Associate Director of Quality Screening & Program Initiatives at GO2 for Lung Cancer has been selected to receive the 2020 Timothy W. Mullett, MD, Lung Cancer Prevention Award. This award is given in recognition of outstanding leadership, devotion, and passion toward preventing lung cancer through education, advocacy, [...]

Bonnie J. Addario Announced as Winner of Lifetime Achievement Award from CURE Media

September 24th, 2020|Hot Topics, News, Press Releases|

Congratulations to our own Bonnie J. Addario for receiving the Lifetime Achievement Award from Cure Magazine. We are so proud! Bonnie’s awe-inspiring message of empowerment has reached millions. CRANBURY, N.J.--(BUSINESS WIRE)--CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million [...]

Update for Week of September 21, 2020 to the Joint Statement on COVID-19 From Lung Cancer Advocacy Groups

September 21st, 2020|Hot Topics, News, Science and Research|

As of September 18, 2020, the US has had 6.7 million cases of COVID-19, with just over 198,000 deaths. The Midwest is leading new cases, with 8 cities in Wisconsin appearing on The New York Times list of the 20 metro areas with fastest-growing cases. With the run-up to [...]

Are You Biomarker Savvy?

September 16th, 2020|Hot Topics|

Every person’s cancer is different. Between all of the lung cancer treatment options available, how can you and your treatment team identify the best path for your individual case? Enter: comprehensive biomarker testing. Comprehensive biomarker testing (also called molecular testing) looks for biological changes, like EGFR or ALK, that [...]

FDA Approves Gavreto (pralsetinib) for the Treatment of Advanced NSCLC with Tumors Having Changes in RET

September 9th, 2020|Hot Topics, News, Science and Research|

On September 4th, 2020, the Food and Drug Administration (FDA) approved Gavreto (pralsetinib) for the treatment of advanced non-small cell lung cancer (NSCLC) with tumors having changes in RET. The FDA based their approval on the results of the clinical trial ARROW which showed that patients receiving Gavreto (pralsetinib) [...]

New FDA Approval for FoundationOne Liquid CDx Biomarker Testing

September 1st, 2020|Hot Topics, News, Science and Research|

On August 26th, 2020, the Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx for comprehensive liquid biopsy biomarker testing for patients with any solid tumor. The FDA based their approval on analysis from multiple clinical validation studies which showed that FoundationOne Liquid CDx is very sensitive and [...]

Recognizing Excellence

August 20th, 2020|Hot Topics, News|

GO2 for Lung Cancer is proud to recognize the Central Virginia VA Health Care System (CVHCS), Hunter Holmes McGuire VAMC as currently the only VA medical facility in the country to be designated as a Screening Center of Excellence within our Centers of Excellence: Screening and Care Continuum national network. [...]

Keith Perry: Endurance Athlete, Husband, Dad, Friend, and Stage 2 Lung Cancer Patient

August 20th, 2020|Community Engagement, Hot Topics, Stories of Hope|

Like many seasoned athletes, the last thing on Keith Perry’s radar was developing lung cancer. But less than two years ago, he received that diagnosis and believed his racing days were over. But despite a stage 2 diagnosis and a full left pneumonectomy, followed by chemotherapy [...]

This Physician-Scientist Wants to Personalize Radiation Treatment

August 18th, 2020|Hot Topics, News, Science and Research|

Dr. Moding, recipient of the 2020 Young Investigator Award Which patients respond to radiation treatment and why? That’s the question that Everett Moding, MD, PhD, is trying to understand. Dr. Moding, recipient of the 2020 GO2 for Lung Cancer / ASCO Foundation Conquer Cancer Young Investigator Award, is [...]

FDA Approval: Access to New Comprehensive Liquid Biopsy Biomarker Testing

August 10th, 2020|News, Press Releases, Science and Research|

On August 7th, 2020, the Food and Drug Administration (FDA) approved the Guardant 360 CDx for comprehensive biomarker testing for patients with any solid tumor. The FDA based their approval on data from the clinical trials FLAURA and AURA3 as clinical validation that patients receiving liquid biopsy biomarker testing [...]

Turn Your Passion Into Progress

July 23rd, 2020|Community Engagement|

What does a birthday, handmade jewelry, a wedding, an outdoor yoga class and a cancerversary all have in common? They can all be opportunities to fundraise for more breakthroughs in lung cancer treatment. Adding a fundraising component to what you are already doing is easier than you think! Every [...]

GO2 for Lung Cancer to Honor Charles Swanton, M.D., Ph.D., FRCP, FMedSci, FRS with the 2020 Bonnie J. Addario Lectureship Award

July 23rd, 2020|Hot Topics, News, Press Releases|

GO2 for Lung Cancer recognizes Professor Swanton for genetic research transforming lung cancer treatment San Carlos, CA and Washington, D.C., July 23, 2020 – GO2 for Lung Cancer (GO2 for Lung Cancer) will present Charles Swanton, M.D., Ph.D., FRCP, FMedSci, FRS senior group leader at the Francis Crick Institute [...]

New Draft Recommendation Expands Eligibility for Those at High Risk for Lung Cancer

July 7th, 2020|Hot Topics, News|

A step forward in preventative screening for lung cancer. The U.S. Preventive Services Task Force (USPSTF) issued its 2020 draft recommendation on annual lung cancer screening using low-dose computed tomography (LDCT) today. This draft recommendation will replace the 2014 recommendation that established LDCT lung cancer screening as a recommended preventive [...]

Lung Cancer Registry Launches Landmark Survey on Women’s Sexual Health

June 23rd, 2020|Hot Topics, News, Press Releases, Science and Research|

WASHINGTON, June 23, 2020 /PRNewswire/ -- The Lung Cancer Registry has launched a landmark new survey on the impact of lung treatments on women's sexual health. The aim is to explore the magnitude of the problem and give researchers and clinicians new insights to improve the quality of life for women lung cancer [...]

FDA approves pembrolizumab for adults and children with TMB-H solid tumors

June 18th, 2020|Hot Topics, News, Science and Research|

On June 16th, 2020, the Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for treatment of all advanced, metastatic cancers with a tumor mutational burden-high (TMB-H) designation. The FDA based their approval on the results of the clinical trial KEYNOTE-158 which showed that a high percentage of patients receiving [...]

Worth The Fight: Taking On Lung Cancer

June 18th, 2020|News|

Jodi Parker, a former oncology nurse who was originally diagnosed with Stage 4 non-small cell lung cancer in 2013, sat down with her son Joey, one of her primary caregivers, to discuss what motivated her to take an active role in her cancer care. Parker has teamed up with [...]

VA and GO2 for Lung Cancer Partner to Improve Outcomes for Veterans at Risk of Lung Cancer

June 16th, 2020|Hot Topics, News, Press Releases|

A historic milestone was reached today with the exciting announcement that the Department of Veterans Affairs (VA) and GO2 for Lung Cancer (GO2 for Lung Cancer) have established a formal partnership to advance lifesaving screening and care for our military men and women at greater risk for lung cancer.  [...]

We Stand Together

June 2nd, 2020|Advocacy in Action, Hot Topics, News|

At GO2 for Lung Cancer we believe when social injustice rules whether through stigma, unequal access to healthcare, or violent and discriminatory actions, no one wins. We must stand together now, change this wrong, and unite as a nation that is caring, respectful and supporting of all people. We [...]

FDA Approves nivolumab Plus ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

May 27th, 2020|Hot Topics, News, Science and Research|

On May 26, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab), Yervoy (ipilimumab), and two cycles of platinum-doublet chemotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having no changes in EGFR or ALK. The FDA based their [...]

Why I Run

May 21st, 2020|Community Engagement|

Everyone has a story to share. Your voice. Your experiences. Your memories. They are uniquely yours and yet they have the power to build bridges, forge friendships and show others they are not alone.For this year’s Summer Jam Virtual 5K Your Way, we are encouraging everyone to share their story [...]

FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression

May 19th, 2020|Hot Topics, News, Science and Research|

On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having high expressions of PD-L1 (>50%) and no changes in EGFR or ALK. The FDA based their approval on the results of [...]

GO2 for Lung Cancer Names Jennifer C. King, Ph.D. as Chief Scientific Officer

May 13th, 2020|Hot Topics, News, Press Releases, Science and Research|

SAN CARLOS, Calif. and WASHINGTON, May 13, 2020 /PRNewswire/ -- GO2 for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global patient advocacy group dedicated to saving, extending, and improving the [...]

Register Today for the 2020 Virtual Lung Cancer Voices Summit!

May 8th, 2020|Advocacy in Action, Community Engagement, Hot Topics|

REGISTRATION NOW OPEN! This year, we are transforming our annual Advocacy Summit into a free virtual event, June 15-16. Join other lung cancer patients, caregivers, and advocates for an inspiring two-day virtual event to learn about the current state of lung cancer and educate Members of Congress about the [...]

FDA Grants Accelerated Approval to Tabrecta (capmatinib) for Metastatic Non-small Cell Lung Cancer with a Change in MET

May 7th, 2020|Hot Topics, News, Science and Research|

On May 6th, 2020, the Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET. The FDA based their approval on the results of the clinical trial GEOMETRY mono-1 which showed that more patients receiving Tabrecta experienced [...]

April 27 Update on Coronavirus and Lung Cancer

April 27th, 2020|Hot Topics, News|

As of April 24, 2020, the Centers for Disease Control and Prevention (CDC) reports 895,766 cases of COVID-19 and 50,439 COVID-19-associated deaths. As the number of cases continue to rise, the importance of maintaining social distancing and following shelter in place/quarantine orders is central to flattening the COVID-19 curve. [...]

FAQs of Accessing Telehealth

April 23rd, 2020|Advocacy in Action, Hot Topics, News|

During this unprecedented time, health care is quickly evolving with remote or virtual doctor visits, also known as “telehealth.” Opening the door to telehealth allows patients and providers access to continued care while minimizing the risk of possible exposure to COVID-19 in traditional treatment facilities. We’ve partnered with fellow [...]

April 20 Update on Coronavirus and Lung Cancer

April 20th, 2020|Hot Topics, News|

As of April 18, 2020, the Centers for Disease Control and Prevention (CDC) reports 661,712 cases of COVID-19 and 33,049 COVID-19-associated deaths. A recent study conducted by researchers at Stanford University suggests that this number is an underrepresentation of the total number of infected individuals. We must urge caution [...]

April 13 Update on Coronavirus and Lung Cancer

April 13th, 2020|Hot Topics, News|

As of April 11, 2020, the Centers for Disease Control and Prevention (CDC) reports 492,416 cases of COVID-19 and 18,559 COVID-19-associated deaths. The United States now has the highest number of confirmed COVID-19 cases in the world.  These numbers may be an underestimation of the true burden of the [...]

COVID-19 and Anti-discrimination – An Update from Leadership

April 7th, 2020|Advocacy in Action, Hot Topics, News|

Dear Lung Cancer Community, As COVID-19 continues its spread across our communities, we are all aware that our doctors, nurses, and hospitals are managing an unprecedented crisis that has overwhelmed them and impacted our medical supplies and equipment reserves. We know our care teams are doing everything possible to [...]

Q&A with Dr. Brendon Stiles: COVID-19 and Surgery

April 2nd, 2020|Hot Topics|

This update has been written in collaboration with Dr. Brendon Stiles. He is Chair of the Board for the Lung Cancer Research Foundation, a thoracic surgeon at New York-Presbyterian Hospital and an Associate Professor of Cardiothoracic Surgery at Weill Cornell Medicine. Q: COVID-19 and surgery: How long can I [...]

Diversion in Isolating Times

March 31st, 2020|Hot Topics|

By Maureen Rigney, LICSW Director, Support Initiatives GO2 for Lung Cancer The coronavirus and the resulting covid-19 disease have changed everyone’s daily lives. In this blog, Maureen Rigney, our lead social worker and boredom fighter, shares her thoughts on using idle time while at home social distancing. Need a [...]

FDA Approves New First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

March 30th, 2020|Hot Topics, News, Press Releases, Science and Research|

On March 27, 2020, the Food and Drug Administration (FDA) approved Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin as first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA based their approval on the results of the clinical trial CASPIAN which [...]

Update for Week of March 23, 2020 to the Joint Statement on Coronavirus COVID-19 From Lung Cancer Advocacy Groups

March 23rd, 2020|Hot Topics, News|

As cases of the virus surge in countries around the world, with Italy being particularly hard hit, many nations are taking extreme steps to mitigate the outbreak, including whole country lockdowns. Here in the United States, the President declared a national emergency on March 13, 2020. Several states have [...]

Update for Week of March 16, 2020 to the Joint Statement on Coronavirus COVID-19 From Lung Cancer Advocacy Groups

March 16th, 2020|Hot Topics, News|

The World Health Organization officially declared the COVID-19 outbreak a pandemic on March 11, 2020. As cases of the virus surge in countries around the world, with Italy being particularly hard hit, many nations are taking extreme steps to mitigate the outbreak, including whole country lockdowns. Here in the [...]

Coronavirus Response Update

March 11th, 2020|Hot Topics, News|

Dear Members of the Lung Cancer Community, For the past several weeks, we have been closely monitoring the developments and impact around the increased spread of the coronavirus. We want each member of our community to know that your health and well-being is uppermost in our minds and hearts [...]

Statement on the passing of Amory Houghton, Jr. GO2 for Lung Cancer Board Emeritus, former Member of Congress, Chief Executive, Corning Inc.

March 10th, 2020|News|

By Laurie Fenton-Ambrose, CEO, President, and Co-Founder GO2 for Lung Cancer I share the sad news of the passing of one of GO2 for Lung Cancer’s longstanding Board members, Amory Houghton, Jr.  “Amo”, as he was known by family, friends and constituents, was an admired, respected and accomplished businessman [...]

Update for Week of March 9, 2020 to the Joint Statement on Coronavirus COVID-19 from Lung Cancer Advocacy Groups

March 9th, 2020|Hot Topics, News|

As advocacy organizations dedicated to serving the needs of lung cancer patients, all of us are closely monitoring the latest developments related to the outbreak caused by the novel coronavirus, SARS-CoV-2, and the resulting disease, COVID-19. In this update, we have included additional information on facts about COVID-19, symptoms, [...]

Screening Works!

February 20th, 2020|Hot Topics, News, Science and Research|

By James L. Mulshine, MD, Scientific Leadership Board, GO2 for Lung Cancer, Professor, Internal Medicine, Rush University We had another home run for the lung cancer community.  On February 6, 2020 the New England Journal of Medicine published the long awaited results of the NELSON Trial (the Dutch-Belgium Lung [...]

$500,000 Research Grant to Combat Cancer Treatment Resistance Awarded by ALK Positive and GO2 for Lung Cancer

February 6th, 2020|Hot Topics, News, Press Releases, Science and Research|

SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung cancer researchers dedicated to overcoming treatment resistance. This grant funds [...]

Team Captains Baking for the Cause

February 6th, 2020|Community Engagement, Hot Topics|

Laura and Krista at their Cupcake Baking Event Meet Laura Rodriguez, a mother, survivor, and champion for the lung cancer community. When Laura was diagnosed with stage IV ALK+ lung cancer in 2012, her world forever changed. Today, she shows no evidence of disease (NED) thanks to biomarker testing and targeted therapy treatments. Laura and her [...]

The Power of the Patient Voice

January 30th, 2020|Hot Topics, Science and Research|

Patient-reported outcomes (PROs) have been used in cancer clinical trials for more than 20 years. Along with clinical evidence, healthcare decision-makers use PROs to guide both individual patient choice and shared decision making. Unfortunately, the patient voice is often lost in clinical trial development because of inadequate or poor [...]

The Lung Cancer Living Room: Q&A with Danielle Hicks, Chief Patient Officer

January 9th, 2020|Hot Topics, News|

Every month our Lung Cancer Living Room, a patient education and support series, brings hope home to patients and their families around the world. Through presentations by experts in the field, this unrestricted forum covers all topics, from early detection to personalized medicine and beyond. As the first lung [...]

Advances in Lung Cancer Treatment Drops U.S. Cancer Deaths

January 9th, 2020|Hot Topics, News, Press Releases, Science and Research|

GO2 for Lung Cancer points to targeted treatments and early screenings SAN CARLOS, Calif. and WASHINGTON, Jan. 8, 2020 /PRNewswire/ -- Today's report concerning improvements in cancer mortality is welcomed news. The recently released Cancer Statistics 2020 report shows that the decline in lung cancer deaths is driving the decrease in mortality rates for cancer overall. [...]

Year-end Progress for the Lung Cancer Community: Federal Research Funding & the Women and Lung Cancer Research and Preventive Services Act

December 21st, 2019|Advocacy in Action, Hot Topics, News|

For many weeks, our community has been awaiting passage of the Fiscal Year 2020 (FY20) federal budget, which funds the Lung Cancer Research Program. This week, just days before the budget continuing resolution expired, the House and Senate released the long-awaited conferenced agreement that has been signed by the [...]

Stories That Inspire

December 19th, 2019|Hot Topics, Stories of Hope|

From advancements in research and progress on Capitol Hill, to working directly with survivors and families, 2019 has been a monumental inaugural year for us at GO2 for Lung Cancer. At the heart of everything we do is our patient community; you continue to inspire and motivate us every [...]

FDA Approves Tecentriq Plus Chemotherapy as a First-Line Treatment for Metastatic NSCLC

December 5th, 2019|Hot Topics, News, Press Releases, Science and Research|

On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK changes. This approval is based on the [...]

GO2 for Lung Cancer Announces Young Innovators Team Award Recipients

December 3rd, 2019|Hot Topics, News, Press Releases, Science and Research|

SAN CARLOS, Calif., Dec. 3, 2019 -- GO2 for Lung Cancer announced the recipients of the 2019 Young Innovators Team Awards (YITA) today. Two teams of researchers received grants totaling $500,000 for their work developing novel strategies to treat KRAS-mutant non-small cell lung cancer (NSCLC) and examining the impact of age on development, progression, and [...]

“Simply the Best” Dinner and Gala Honors Those Working to Fight Lung Cancer

November 14th, 2019|Hot Topics, Press Releases|

AstraZeneca Announced as 2019 "Simply the Best Award" Honoree SAN CARLOS, Calif. and WASHINGTON DC, November 12, 2019 – GO2 for Lung Cancer (a merger of the Bonnie J. Addario Lung Cancer Foundation and Lung Cancer Alliance) recognized AstraZeneca on November 9 at its 14th annual "Simply the Best" [...]

Know Your Nodules

September 5th, 2019|Hot Topics|

Decoding lung cancer terminology can be tough—but we’re here to make it easier. In this blog, we’ll help you better understand nodules, also known as lesions, coin lesions, growths, or solitary pulmonary nodules. Nodules are abnormal (yet common) spots that may show up on your lung cancer screening scan [...]

Quality of Life

August 29th, 2019|Hot Topics|

Isn’t that what it’s all about? Whether a CT scan detects lung cancer early or treatment navigation helps you receive biomarker testing or a HelpLine staff member virtually holds a hand, enhancing quality of life for you and all the lung cancer community is of paramount importance. Support can be [...]

Welcome to Belong, a New Online Cancer Community

August 21st, 2019|Hot Topics, News, Press Releases|

GO2 for Lung Cancer has partnered with Belong.Life to provide patient and caregiver support and education on the world’s largest social network for cancer patients. Within the GO2 Foundation membership area, our social workers, clinical trial specialists, and survivor-volunteers will provide hope, education, and support for those living with lung [...]

FDA Approves Genentech’s Rozlytrek (entrectinib) for ROS1 Non-Small Cell Lung Cancer (NSCLC) and NTRK-Driven Tumors

August 16th, 2019|Hot Topics, News, Press Releases, Science and Research|

On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor that is NTRK fusion-positive, following progression on other therapies. This [...]

GO2 for Lung Cancer Presents 2019 Bonnie J. Addario Lectureship Award at ILCC

August 2nd, 2019|Hot Topics, News, Press Releases|

GO2 for Lung Cancer is pleased to announce that it presented Solange Peters, MD, PhD, with the 2019 Bonnie J. Addario Lectureship Award for her emphasis on groundbreaking biomarker research, improving access to care for lung cancer patients worldwide, and supporting the advancement of women in oncology. GO2 Foundation honored Prof. [...]

Lung Cancer Stigma’s Harmful Consequences

July 10th, 2019|Hot Topics, Science and Research|

Despite increased awareness around lung cancer in recent years, the stigma associated with the disease remains an issue for the lung cancer community. Beyond the known psychosocial issues associated with this stigma, our research has revealed that both patients and oncologists feel that the stigma can actually affect the level of [...]

New Treatment Approved for Metastatic Small Cell Lung Cancer

June 18th, 2019|Hot Topics, News, Press Releases, Science and Research|

On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Though pembrolizumab is an established treatment option [...]

Early Screening Equals Early Diagnosis

June 18th, 2019|Hot Topics, News, Science and Research|

GO2 for Lung Cancer’s recently published scientific paper found that lung cancer screening programs can successfully detect lung cancer early with the majority of lung cancers diagnosed at stage 1 or limited stage. Importantly, outcomes at academic and nonacademic sites were compared and the data confirmed that responsible screening [...]

Register for the UNITED Portland Run/Walk, June 22!

February 26th, 2019|Community Engagement, Hot Topics|

This year, for the first time in Portland, two of the leading lung cancer organizations are joining forces to create one of the largest run/walk events for lung cancer on the west coast…because together we are stronger. Join Lung Cancer Alliance and Bonnie J. Addario Lung Cancer Foundation at Laurelhurst Park on Saturday, [...]

LCA Joins ACS CAN in Efforts to Protect Patient Access to Lifesaving Treatment

January 17th, 2019|Hot Topics, News|

Thursday, January 17 – Lung Cancer Alliance joins a long list of leading patient advocacy groups in support of American Cancer Society Cancer Action Network’s (ASC CAN) advertising campaign, urging the U.S. Administration and Congress not to limit patient access to lifesaving medications covered under Medicare, and to ensure [...]

Don’t Guess, Test!

January 17th, 2019|Hot Topics, Stories of Hope|

By Kimberly Buchmeier My name is Kimberly Buchmeier and I am from a small town in Southeast Nebraska.  I am a mother, wife, grandmother, daughter, sister, aunt, cousin, friend and a six-year lung cancer survivor.  In 2011, at age 37, I was diagnosed with non-small cell adenocarcinoma. I [...]

New Year, New You!

January 3rd, 2019|Hot Topics|

Goodbye 2018, hello 2019! With the new year comes new opportunity to recommit to your health and well-being. If you’re part of the 41% of Americans looking to set a New Year resolution, we can help! Here are four worthy commitments to consider this year. FIND SUPPORT: Support in your [...]

Get Well Soon Justice Ginsburg

December 21st, 2018|Hot Topics, News|

On behalf of the lung cancer community we serve, we send our best wishes for a speedy recovery to Supreme Court Justice Ruth Bader Ginsburg. According to a Supreme Court press release, Justice Ginsburg is now resting comfortably after undergoing a pulmonary lobectomy today. Two nodules, found to be [...]

Giving—Why Not?

December 12th, 2018|Hot Topics|

With the season of giving upon us, now is the perfect time to join the fight against lung cancer. Over 234,000 people were diagnosed with lung cancer this year, making it the leading cause of cancer death for both men and women across all ethnicities. You can help us [...]

New Combination Treatment Approved for Non-Small Cell Lung Cancer

December 7th, 2018|Hot Topics, News|

The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. This is the first four drug combination [...]

LCA partners with GRAIL, UCL, and ULCH on Newly Announced SUMMIT Study

December 4th, 2018|Hot Topics, News|

Monday, December 3, 2018 –Today, Lung Cancer Alliance, in collaboration with GRAIL, Inc., a healthcare company focused on the early detection of cancer, UCL (University College London) and University College London Hospitals National Health Service (NHS) Foundation Trust (UCLH) announced plans to initiate the SUMMIT study in early 2019. [...]

Honor and Salute the Veterans In Your Life

November 9th, 2018|Hot Topics|

By Rick Sherlock, Lung Cancer Alliance Board Member and retired Major General of the United States Army On this Veteran’s Day, we honor and salute the dedicated service of the brave men and women that protect our freedoms. In all they do for our country, it is our responsibility [...]

2018 Lung Cancer Support Group Facilitator Award

November 5th, 2018|Hot Topics, News|

Monday, November 5, 2018 -- Today, Lung Cancer Alliance presented the 2018 Lung Cancer Support Group Facilitator Award to Catherine Paykin, LCSW-R, who runs a support group at New York University Perlmutter Cancer Center. The Lung Cancer Support Group Facilitator Award recognizes the uncommon dedication of a support group facilitator. Members [...]

FDA Approves New Treatment for ALK+ NSCLC Patients

November 2nd, 2018|Hot Topics, News|

Friday, November 2, 2018 – Today the Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (LORBRENA) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease [...]

LCA Named 2018 Top Rated Nonprofit

November 2nd, 2018|Hot Topics, News|

Friday, November 2, 2018 - Today Lung Cancer Alliance was named a “2018 Top-Rated Nonprofit” by GreatNonprofits, the leading provider of user reviews of charities and nonprofits. The Top-Rated Nonprofit Award is based on the rating and number of reviews that Lung Cancer Alliance received from volunteers, donors and aid [...]

LCA Partners with UAB Comprehensive Cancer Center to Help At-Risk, Underserved Communities

November 1st, 2018|Hot Topics, News|

Washington, D.C. - November 1, 2018 –Lung Cancer Alliance (LCA) today announced a $1.6M grant from the Bristol-Myers Squibb Foundation to partner with the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center to establish the Alabama Lung Cancer Awareness, Screening and Education (ALCASE) program. The three-year effort will [...]

LCA Launches Nationwide Screening Awareness Campaign

October 31st, 2018|Hot Topics, News|

 “What About Your Lungs?” Campaign Urges Individuals At-Risk for Lung Cancer to Talk to Their Doctor About Life-Saving Screening Washington, DC [Wednesday, October 31, 2018]—Responding to the need to increase national awareness about lung cancer screening and encourage those at risk to talk with their doctor, Lung Cancer Alliance [...]

FDA Approves New Combination Treatment for NSCLC

October 31st, 2018|Hot Topics, News|

Tuesday, October 30, 2018 – Today the Food and Drug Administration (FDA) approved immunotherapy drug, pembrolizumab, also known as KEYTRUDA, in combination with chemotherapies, carboplatin, and either paclitaxel or nab-paclitaxel as a first-line treatment for patients with metastatic squamous non-small cell lung cancer (NSCLC). The results of the randomized [...]

LCA Urges CMS to Remove Barriers to Screening

October 25th, 2018|Hot Topics, News|

In a number of communications to the Centers for Medicare and Medicaid Services (CMS), Lung Cancer Alliance urged the national CMS office to 1) instruct all local Medicare contractors that lung cancer screening coverage is available in all settings including Independent Diagnostic Testing Facilities across the country and 2) [...]

Now Is the Time for Advocacy At Home!

October 24th, 2018|Hot Topics|

By Elridge Proctor, MPA, Director of Health Policy We have come a long way, but still have far more work to do in raising awareness about the profound impact that lung cancer has on Americans in every state across the nation. November is Lung Cancer Awareness Month and mid-term elections. [...]

Doing My Part

October 18th, 2018|Community Engagement, Hot Topics|

By Michelle McMahon My connection to lung cancer began when I was a teenager. I lost my mom to this disease just before her 53rd birthday. Some 33 years later I was handed the same lung cancer diagnosis in the form of Bronchoalveolar Carcinoma (BAC). I was 49 years [...]

New First-Line Treatment Approved for NSCLC with an EGFR Mutation

September 28th, 2018|Hot Topics, News|

Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based on a randomized trial that showed a significant improvement in [...]

Trial Results Show Screening Significantly Reduces Lung Cancer Mortality Rates

September 25th, 2018|Hot Topics, News|

Washington, DC [September 25, 2018] – Lung Cancer Alliance (LCA) applauds the results of the Dutch-Belgium Lung Cancer Screening trial (NELSON) announced today in Toronto, Canada at the IASLC 19th World Conference on Lung Cancer. The NELSON study was a population-based, controlled trial that enrolled 15,792 individuals, who were [...]

Lung Cancer Stigma: Where Are We Now?

September 25th, 2018|Hot Topics, News|

Lisa Carter-Harris, PhD, APRN, ANP-C By Lisa Carter-Harris, PhD, APRN, ANP-C, Indiana University School of Nursing, Indianapolis, IN This year, I joined Lung Cancer Alliance in replicating a national survey, that was first done in 2008, to examine the perspectives of patients, oncologists and the general public on [...]

LCA’s Research Showcased on a World Stage

September 18th, 2018|Hot Topics, News|

The Lung Cancer Alliance team is heading to IASLC's World Conference on Lung Cancer (WCLC), Toronto, Canada from September 23-28, 2018 and will be presenting on hot topics in the field of lung cancer including: clinical trials, long-term survivorship, stigma, advocacy and much more! Below are details on our whereabouts [...]

An Unexpected Path

September 11th, 2018|Hot Topics, News|

Shanen M. Sherrer, PhD By Shanen M. Sherrer, PhD Shanen M. Sherrer, PhD, is the Assistant Professor of Biochemistry, Department of Chemistry and Biochemistry, St. Mary’s College of Maryland. We interviewed Dr. Sherrer to find out about her career as a cancer researcher, how attending a Shine [...]

Tribute to Senator John McCain

August 28th, 2018|Hot Topics, News|

Lung Cancer Alliance (LCA) joins the millions of Americans and others from around the world in remembering the extraordinary life of Senator John McCain (R-AZ) who passed away from brain cancer on August 25, 2018.  He was a true American hero who embodied values that we admire and seek [...]

Make a Difference TODAY – 8/20!

August 20th, 2018|Hot Topics, News|

Advocacy Action Day — August 20, 2018 Since our National Advocacy Summit on July 10-12, where over 120 lung cancer advocates joined forces in Washington, DC to meet with their elected official and demand that lung cancer be recognized as a national priority, we have seen nearly 50 representatives [...]

LCA Advocates for Patient Access to Robotic Radiosurgery (Cyberknife)

August 8th, 2018|Hot Topics|

Last month, Lung Cancer Alliance (LCA) submitted detailed comments to Noridian Healthcare Solutions, a Medicare contractor, regarding the unintended consequences and patient access implications to reductions in healthcare reimbursement for CyberKnife, robotic radiosurgery/stereotactic body radiation. In response to LCA’s comment letter and other stakeholder feedback, Noridian modified their policy [...]

Meet Anita! Our Screening Expert

June 28th, 2018|Hot Topics, News|

By Anita McGlothlin, Associate Director of Science and Regulatory Policy, Lung Cancer Alliance Greetings! I am Anita McGlothlin, the Associate Director of Science and Regulatory Policy at Lung Cancer Alliance (LCA). I can’t wait to meet you in person at a future LCA event. In the interim, I’m excited [...]

My Difference Maker

June 21st, 2018|Hot Topics, Stories of Hope|

Patty (third from right) and her family By Patty Watkins I learned that I had stage 4 adenocarcinoma in February 2014 and was only given two days to live, but fortunately survived beyond this bleak, initial diagnosis. In May 2014 I had my tumor tissue tested for [...]

Expanding the Reach of Precision Medicine

June 7th, 2018|Hot Topics, News|

By Jennifer C. King, PhD, Director of Science and Research at Lung Cancer Alliance Expanding the Reach of Precision Medicine Lung cancer research was everywhere at the American Society of Clinical Oncology (ASCO) conference held June 1-5.  The ASCO President, Bruce E. Johnson, MD, contrasted this meeting with the [...]

My Mom is a Lung Cancer Survivor

May 31st, 2018|Hot Topics, Stories of Hope|

By Congresswoman Suzanne Bonamici (D-OR-01), Member of the Congressional Lung Cancer Caucus As a policymaker, I know we must do more to prevent lung cancer and support patients – especially women – who are battling this devastating disease. I’m proud to help lead the bipartisan Women and Lung Cancer Research [...]

Clinical Trial Myths Busted!

May 17th, 2018|Hot Topics, News|

Clinical trials are an important consideration in your lung cancer treatment path, but finding the right one can be overwhelming. Thanks to our Clinical Trial Matching Service partners, Antidote, we busted some of the five most common myths about clinical trials. Myth #1: I can’t take part in a clinical [...]

A Champion for Lung Cancer Screening

May 14th, 2018|Hot Topics, Stories of Hope|

Cecelia Brewington, MD is a board-certified practicing radiologist, radiology administrator and professor who serves as Medical Director of UT Southwestern Medical Center’s CT Lung Cancer Screening Program; a program she helped found. We interviewed Dr. Brewington to find out more about her 25 year career, what she wants people to [...]

What Type of Volunteer Are You?

May 4th, 2018|Hot Topics|

It’s not a one-size-fits-all approach when it comes to getting involved in the fight against lung cancer. Below are the four most popular types of volunteers we see and opportunities that apply to each. What kind are you? The Newbie There is never a bad time to join the [...]

Commit to Clean Air with these Simple Changes

April 20th, 2018|Hot Topics|

Each day we take about 23,040 breaths! Needless to say, the quality of the air we breathe is very important. Pollution of our air comes in many forms from vehicle and diesel exhaust to industrial and residential emissions.  Unfortunately, these substances contaminate the air and can lead to long-term [...]

The New Frontier: Immunotherapy Combinations

April 19th, 2018|Hot Topics, News|

At the annual American Association of Cancer Research (AACR) conference, scientists presented new research on what they called “The New Frontier in Lung Cancer” – immunotherapy combinations. The Big Question: Do Combinations Work? If we take the new immunotherapy drugs (like Keytruda, Opdivo, or Tecentriq) that have shown positive [...]

Grieving a Cancer Diagnosis and How to Deal

April 13th, 2018|Hot Topics|

By Trudy Lechner, RN, BA, CDE, Medical and Bereavement Counselor Trudy is a Registered Nurse and Bereavement Counselor who has worked in the field of Death and Dying for 26 years. The theory referenced below was established by Dr. Elisabeth Kübler-Ross. I am a lung cancer survivor. I was [...]

Living For My Dad

April 12th, 2018|Hot Topics|

By Rachel Heimler Richard (second from left), Rachel (third from right) and their family. Today would have been the 14th anniversary since my dad, Richard, was diagnosed with lung cancer. Each year, for the past 14 years, we have woken up to a letter from my dad [...]

My Public Health Path to Lung Cancer  

April 6th, 2018|Hot Topics|

By Amy Copeland, MPH, Director of Medical Outreach at Lung Cancer Alliance Public Health Week (April 2-9) got us thinking….What exactly is public health and how does it relate to lung cancer? We sat down with Amy Copeland, Lung Cancer Alliance’s (LCA) Director of Medical Outreach, who received her [...]

Reflections from the Front Lines

March 29th, 2018|Hot Topics|

By Eric H Bernicker, MD - Assistant Professor of Clinical Medicine in Oncology, Institute for Academic Medicine, Assistant Clinical Member, Research Institute, Houston Methodist If you could bring a lung cancer researcher from the 1970s in a time machine to see our present treatment landscape, they would be truly dumbfounded. [...]

Nat’l Advocacy Summit Registration Open!

March 26th, 2018|Community Engagement, Hot Topics, News|

REGISTER TODAY for Lung Cancer Alliance's 10th Anniversary National Advocacy Summit, July 10-12! Don't miss this special opportunity to join fellow lung cancer survivors and advocates in Washington, DC, as we amplify the national call for lung cancer research, early detection and access to high quality of care. At the National Advocacy Summit, you [...]

Take Action for Int’ Women’s Day!

March 8th, 2018|Hot Topics, News|

We remember, celebrate and honor the women who have gone before us, touch our lives today and will impact the future tomorrow. Thursday, March 8th is International Women's Day, a time to stand up for the women in our lives. Lung cancer kills more women than all gynecological cancers [...]

Lung Love Run/Walk Portland, June 23!

February 27th, 2018|Hot Topics|

Lung Love Run/Walk Portland is back and better than ever! Join the lung cancer community and Lung Cancer Alliance on Saturday, June 23rd, 2018 at Laurelhurst Park for a day of family-fun as we walk a 5K to fight lung cancer! Mark your calendars, call your family and friends, [...]

#SaveHerLungs

February 22nd, 2018|Hot Topics|

Lung cancer, the leading cancer killer of women, behaves differently in women than men. But we don’t know why. In order to ignite federal government action around this critical issue to advance research breakthroughs, improve quality of life and increase survival for women and the entire lung cancer community, [...]

Finding Hope in Unexpected Places

February 21st, 2018|Hot Topics, News|

By Curt Hammock As I approached Christmas in 2010, I reflected on just how good I had it. My business was growing, I was riding my motorcycle, playing golf and getting ready to celebrate my wife, Elaine’s, birthday that month. During that time, I had a constant nose bleed [...]

LCA Praises Bipartisan, Bicameral Congressional Leadership on Women’s Health Imperative

January 31st, 2018|Hot Topics, News|

Senators Marco Rubio (R-FL) and Dianne Feinstein (D-CA) and Representatives Frank LoBiondo (R-NJ), Rick Nolan (D-MN), Barbara Comstock (R-VA) and Suzanne Bonamici (D-OR) Bring Priority Focus to Accelerated Research and Screening Services for Women Impacted by Lung Cancer January 30, 2018 – Today, Lung Cancer Alliance (LCA) hailed the reintroduction [...]

How to Ask for Help

January 25th, 2018|Hot Topics|

A lung cancer diagnosis can be overwhelmingly emotional and complicated. To provide support during this confusing period, Lung Cancer Alliance started a national HelpLine dedicated exclusively to lung cancer. Caring, trained support professionals answer calls to help patients, caregivers and loved ones understand their lung cancer diagnosis, available treatment [...]

FDA expands approval of Gilotrif (afatinib) for NSCLC

January 17th, 2018|Hot Topics, News|

Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q and G719X may now take Gilotrif. Gilotrif, an oral, once-daily [...]

Get Ready for a Groundbreaking Year!

December 19th, 2017|News|

Welcome to 2018! We have so much to look forward to, but there is also a lot of hard work ahead. No matter where you find yourself on your journey -- recently diagnosed, in treatment or a 20-year survivor – Lung Cancer Alliance offers you a home for support [...]

A Message from Our President

December 19th, 2017|Hot Topics, News|

Dear Friend, As 2017 prepares to come to a close, let’s take this moment to reflect upon what we have accomplished to improve survivorship, provide support and bring our community together in a lasting and meaningful way. Together we secured more federal research funding, helped patients navigate clinical trials [...]

Starting 2018 With a Full Tank

December 18th, 2017|Hot Topics|

By Kristin Bramell, Director of Philanthropy, Lung Cancer Alliance 2017 saw its share of successes, but it has not changed the fact that 427 people die each day of lung cancer. The New Year offers hope for members of our community, including those at risk and survivors of this deadly [...]

Science & Research Advances in 2017

December 14th, 2017|Hot Topics, News|

By Jennifer C. King, PhD, Director of Science & Research at Lung Cancer Alliance Research on the treatment of lung cancer has been moving quickly and 2017 was no different. Precision medicine was a key theme this year - there have been many treatment advances that depend on the [...]

LCA Participates in Inaugural Meeting of National Lung Cancer Roundtable

December 12th, 2017|Hot Topics, News|

Tuesday, December 12, 2017 – Today, Laurie Fenton Ambrose, President and CEO of Lung Cancer Alliance (LCA), along with a coalition of leading healthcare professionals, patients, government and non-governmental organizations, is joining the American Cancer Society for the inaugural meeting of the National Lung Cancer Roundtable. The event, taking [...]

2017 Support Group Facilitator Award

December 12th, 2017|Hot Topics, News|

Tuesday, December 12, 2017 -- We are thrilled to announce Kerri Susko, LISW-CP of Greenville Health System, SC as the recipient of LCA's 2017 Support Group Facilitator Award. Each year the award is given to a lung cancer support group facilitator who goes above and beyond to bring support [...]

Preserve Access to Community-Based Care

December 11th, 2017|News|

With just days remaining in the legislative calendar, Congress could leave town without fixing an error in Medicare reimbursements that could make it difficult for people with lung cancer and Medicare insurance coverage to receive community-based treatments. Lung Cancer Alliance is working alongside the Community Care Access Coalition – [...]

November is Just the Beginning

December 7th, 2017|Hot Topics, News|

LCAM 2017 This November was the most impactful Lung Cancer Awareness Month (LCAM) to date! With your efforts, time and ongoing support we were able to reach more people, raise more awareness and ignite more change than ever before. Thanks to all those who came out to an LCAM [...]

Coping with Fatigue

November 30th, 2017|Hot Topics, News|

This week we held the fourth and final Coping Series webinar of 2017, addressing one of the most common symptoms and side effects experienced by lung cancer patients and survivors: fatigue. Over 90% of cancer patients experience fatigue during treatment and around 35% continue to experience fatigue up to [...]

Awareness Happens All Year

November 28th, 2017|Hot Topics, News|

Awareness during Lung Cancer Awareness Month is important, but it is vital that the campaign continue all year. Chris Davis, LCA's manager of media relations, provided helpful tips for individual awareness efforts to Mediaplanet. Read on.

Animated Feelings

November 20th, 2017|Hot Topics, Stories of Hope|

Nina Beaty was diagnosed with small cell lung cancer (SCLC) in January 2014 after a low-dose CT scan. More than a year later, she enrolled in an immunotherapy clinical trial using the drug Opdivo. As a granddaughter of Broadway composer Richard Rodgers, Nina comes by her creativity naturally. She [...]

A Lung Cancer Hero at Home

November 14th, 2017|Hot Topics|

Sheila Ross, a pioneering lung cancer advocate who founded Lung Cancer Alliance’s presence on Capitol Hill, was recently profiled by the Annapolis, Maryland-based Capital Gazette. The article traces both Sheila’s cancer journey and the advocacy measures that brought heightened awareness and landmark legislation on low dose CT screening for [...]

A Veteran Versus Cancer

November 9th, 2017|Stories of Hope|

Ed and his dog, Molly. By Ed Fox, U.S. Army Veteran and Lung Cancer Survivor Lung cancer has been on my radar for some time now because both my father and sister died from this disease. I did everything I possibly could to prevent it: regular screenings, [...]

Marilu Henner Talks Lung Cancer on Today

November 7th, 2017|Hot Topics, News|

Tuesday, November 7, 2017 -  Today, actress Marilu Henner shared her personal story as a lung cancer caregiver on Megyn Kelly Today, the third hour of NBC's national morning show Today. During Lung Cancer Awareness Month, Henner and her husband, Michael Brown, are opening up about Brown's 2003 diagnosis with [...]

LCA Partners with Memorial Sloan Kettering Cancer Center and the New York University School of Medicine on CASTL Initiative

November 6th, 2017|Hot Topics, News|

Monday, November 6, 2017 – Today, Lung Cancer Alliance (LCA) joins the Memorial Sloan Kettering Cancer Center (MSK) and the NYU School of Medicine (NYU) to announce the launch of the Cessation And Screening To Save Lives (CASTL) Initiative. The project, which is supported by funding from the National [...]

In Harvey’s Wake, A Doctor Remembers Houston’s Strength

October 25th, 2017|Community Engagement, Hot Topics, Stories of Hope|

By Daniel Gomez, MD, Department of Radiation Oncology, Division of Radiation Oncology, MD Anderson Cancer Center Despite the numerous warnings in the week before the storm, I don’t think that many of us grasped how impactful Hurricane Harvey would be.  For me, this profound event surprisingly had many parallels [...]

24 Hours of Golf

October 12th, 2017|News|

Curt and his friends at this year's event. By Curt Groebner It all started in mid-summer 2008, when my buddy and I were working our summer job at a local golf course and looking for something fun to do. As a couple of crazy college kids seeking a [...]

Story of Hope: Cecilia Izzo

September 28th, 2017|Stories of Hope|

I am Chair of Lung Cancer Alliance's newly formed Washington State Chapter. An eight year (and counting) lung cancer survivor, I am primarily responsible for LCA's activities in Western Washington, including forging relationships with hospitals and medical professionals, fundraising, and public outreach. I am a regular visitor to both [...]

National Lung Cancer Roundtable Forms to Increase Screening and Reduce Lung Cancer Deaths

September 28th, 2017|Hot Topics|

Lung Cancer Alliance and a coalition of leading professional, government and non-governmental organizations joined the American Cancer Society to announce they will be coming together to form the National Lung Cancer Roundtable to accelerate the nation's efforts to reduce mortality from lung cancer. The group will focus on ensuring [...]

FDA Approves First Combination of Chemotherapy and Immunotherapy for Lung Cancer Patients

September 28th, 2017|Hot Topics|

Today, the Food and Drug Administration (FDA) approved the first combination of chemotherapy and immunotherapy for patients with lung cancer. Patients with metastatic, nonsquamous, non-small cell lung cancer can now take Keytruda (pembrolizumab) immunotherapy along with chemotherapy (pemetrexed and carboplatin) as a first line of treatment for their lung [...]

A Second Chance

July 7th, 2017|Hot Topics|

By Gary Stumpf Gary hooks success. As with many, I accidentally found my lung cancer. Last fall, a persistent cough brought me to the doctor (thanks to my wife’s insistence). A CT scan, followed by a lung biopsy, confirmed I had stage 4 adenocarcinoma. Further testing found [...]

Beat the Heat!

July 5th, 2017|News|

Summer is heating up and that can play a role in cancer treatment side effects. While going through lung cancer treatment, such as chemotherapy, radiation, targeted therapies or surgery, it is important to find ways to escape the heat. Here are some helpful tips to keep you cool in [...]

2,800 Miles to the Summit

June 29th, 2017|News|

Mary and her husband By Rev. Dr. Mary Holder Naegeli Rev. Dr. Mary Naegeli serves as the Associate Chaplain at John Muir Medical Center in California. She is also an almost-four-year lung cancer survivor. She uses her own experience with cancer to help guide and support patients [...]

This One’s For Sunny

June 9th, 2017|News|

Sunny by Deena Cook We met Sonia “Sunny” Janin at the first Lung Cancer Alliance National Advocacy Summit we attended in September 2014. This event changed my life and Sunny was an important part of that change. There were five other women from Maryland in our group; [...]

My Lucky Break!

May 25th, 2017|News|

Dann (center) at Lung Love Run/Walk Portland. By Dann Wonser Eleven years ago, in 2006, I got the luckiest "break" of my life: I broke my ribs. While that may not seem all that lucky, those broken ribs led to an X-Ray, which led to the discovery [...]

Coping Series: Digestive Problems

May 2nd, 2017|News|

Last week we held the second discussion in our Coping Webinar Series, focused on the most common side effects of lung cancer treatment, digestive problems, including nausea, vomiting, constipation and diarrhea. We sat down with Director of Palliative Care at Carolinas Healthcare System, Niki Koesel ANP, ACHPN, FPCN and [...]

Go to Top